Document:

EX-10.01

 Exhibit 10.01 

CEPHEID 
 2550 Great
America Way 
 Santa Clara, California 95054 

EMPLOYMENT AGREEMENT 
 Dear John: 

We are pleased to offer you this Employment Agreement setting forth the terms and conditions of your continued employment as the Chief Executive Officer of
Cepheid, effective on July 26, 2016 (the “Effective Date”), on the terms set forth below (this “Employment Agreement”).

This Employment Agreement amends, restates and supersedes in its entirety the letter agreement you entered into with Cepheid on January 24, 2007, as amended
on February 21, 2008 (collectively, the “Prior Agreement”). In this Employment Agreement, “Cepheid” means Cepheid, a California corporation, and any successor or assign to substantially all the
business and/or assets of Cepheid. 
  

	 	1.	Position. You will remain employed by Cepheid as its Chief Executive Officer until termination pursuant to Section 6. You will continue to be nominated to serve on Cepheid’s Board of
Directors for so long as you are Cepheid’s Chief Executive Officer. You will continue to have overall responsibility for the management of Cepheid and report directly to its Board of Directors. During your employment, you will
continue to be expected to devote your full working time and attention to the business of Cepheid, and you will not render services to any other business without the prior approval of the Board of Directors (not to be unreasonably withheld) or,
directly or indirectly, engage or participate in any business that is competitive in any manner with the business of Cepheid. The foregoing, however, will not preclude you from engaging in reasonable community, school or charitable activities
or acting as a director of any company that does not compete with Cepheid with the permission of the Board of Directors (not to be unreasonably withheld). You will be expected to comply with and be bound by Cepheid’s operating policies,
procedures and practices that are from time to time in effect during the term of your employment. 

  

	 	2.	Base Salary. Your base annual salary will be $735,000, payable in accordance with Cepheid’s normal payroll practices with such payroll deductions and withholdings as are required by law (your
“Base Salary”). The Compensation and Organizational Development Committee of Cepheid’s Board of Directors (the “Compensation Committee”) will review your base annual salary on an
annual basis. 

  

	 	3.	Annual Performance Bonus. During the Term (as defined below) you will be eligible to receive an annual cash bonus under Cepheid’s applicable executive bonus plan (the “Incentive
Plan”), with a target amount equal to one hundred percent (100%) of your Base Salary, based upon the achievement of performance objectives established by the Board of Directors, or the Compensation Committee, and subject to the terms of
the Incentive Plan. You have no minimum annual bonus commitment. The Compensation Committee will review your Target Bonus and the Incentive Plan on an annual basis and may, in its sole discretion, make adjustments to the target or maximum
bonus amounts, bonus objectives and other terms. Any bonus determined to be payable under the Incentive Plan will be paid no later than the fifteenth (15th) day of the third (3rd) month following the end of Cepheid’s taxable year in which such bonus is earned. 

  

	 	4.	Equity Compensation. Your existing equity awards shall continue to be governed by the terms of such awards, as modified by this Employment Agreement. The Compensation Committee may, in its sole
discretion, award you other equity-based awards in the future. 

  

	 	5.	Other Benefits. You will be entitled to the following additional benefits: 

  

	 	a.	You will continue to be eligible for the normal health insurance, 401(k), employee stock purchase plan and other benefits offered to all Cepheid senior executives. 

	 	b.	Cepheid will pay your expenses incurred for weekly travel between Illinois or Florida and the Bay Area. The Compensation Committee may review this travel coverage on an annual basis and may, in its discretion,
modify these arrangements. 

  

	 	c.	During the term of your employment, you will be authorized to incur necessary and reasonable travel expenses, including entertainment and other business expenses, in connection with your duties to Cepheid. Cepheid
will reimburse you for such expenses upon presentation of an itemized account and appropriate supporting documentation, all in accordance with Cepheid’s generally applicable policies. 

 

	 	6.	Employment and Termination. Your employment with Cepheid will be at-will and may be terminated by you or by Cepheid at any time for any reason as follows: 

 

	 	a.	Your employment will automatically terminate upon the date on which another individual is appointed by Cepheid to serve as Cepheid’s Chief Executive Officer or, such later date as is mutually agreed between you and
the Board (such date, the “Retirement Date” and such termination, a “Termination Due to Retirement”), unless your employment is earlier terminated pursuant to Sections 6(b) through 6(f) below;

  

	 	b.	You may terminate your employment upon written notice to the Board of Directors at any time for “Good Reason,” as defined below (an “Involuntary Termination”); 

 

	 	c.	You may terminate your employment upon written notice to the Board of Directors at any time in your discretion without Good Reason (“Voluntary Termination”); 

 

	 	d.	Cepheid may terminate your employment upon written notice to you at any time following a determination by the Board of Directors that there is “Cause,” as defined below, for such termination
(“Termination for Cause”); 

  

	 	e.	Cepheid may terminate your employment upon written notice to you at any time in the sole discretion of the Board of Directors without a determination that there is Cause for such termination (“Termination
without Cause”); and 

  

	 	f.	Your employment will automatically terminate upon your death or upon your Disability as determined by the Board of Directors. 

  

	 	g.	Notwithstanding anything to the contrary in this Employment Agreement, (i) any reference herein to a termination of your employment is intended to constitute a “separation from service” within the meaning of
Section 409A of the Internal Revenue Code of 1986, as amended (the “Code”) and Section 1.409A-1(h) of the regulations promulgated thereunder, and shall be so construed, and (ii) no payment will be made or become due to you
upon termination of your employment unless such termination constitutes a “separation from service” within the meaning of Section 409A of the Code. 

  

	 	7.	Term. The period between the Effective Date and the date your employment terminates under this Employment Agreement is referred to herein as the “Term.” You agree to
resign immediately upon request of Cepheid from your directorship upon (i) termination of your employment for any reason or (ii) the date you cease to serve as a Cepheid’s Chief Executive Officer for any reason.

  
 2 

	 	8.	Definitions. As used in this Employment Agreement, the following terms have the following meanings: 

  

	 	a.	“Good Reason” means any of the following taken without your written consent and provided (a) Cepheid receives, within one hundred and eighty (180) days following the date on which you know of the
occurrence of any of the events set forth in clauses (i) through (v) below, written notice from you specifying the specific basis for your belief that you are entitled to terminate employment for Good Reason, (b) Cepheid fails to cure the event
constituting Good Reason within thirty (30) days after receipt of such written notice thereof (if such event is curable), and (c) you terminate employment within thirty (30) days following expiration of such cure period: (i) a significant
diminution in the nature or scope of your authority, title, function or duties; (ii) a ten percent (10%) reduction in your Base Salary or a 25% reduction in your Target Bonus opportunity (in either case, unless either such reduction is part of an
officer-wide program to reduce expenses); (iii) any material breach of the terms of this Employment Agreement by Cepheid; (vi) Cepheid requiring you to be based at any office or location more than fifty (50) miles from Cepheid’s current
headquarters in Sunnyvale, California; or (v) a failure of any successor or assignee to Cepheid to assume this Employment Agreement. 

  

	 	b.	“Cause” means a good faith determination by the Board of Directors, in its sole discretion, that any of the following has occurred: (a) your failure to perform any reasonable and lawful duty of
your position or failure to follow the lawful written directions of the Board of Directors after being given written notice of such failure by the Board of Directors and fifteen (15) days in which to cure your performance, provided that such notice
will be required only with respect to the first failure; (b) commission of an act that constitutes misconduct and is injurious to Cepheid or any subsidiary; (c) conviction of, or pleading “guilty” or “no contest” to, a felony
under the laws of the United States or any state thereof; (d) committing an act of fraud against, or the misappropriation of property belonging to, Cepheid or any subsidiary; (e) commission of an act of dishonesty in connection with your
responsibilities as an employee and affecting the business or affairs of Cepheid; (f) breach of any confidentiality, proprietary information or other agreement between you and Cepheid or any subsidiary; or (g) failure or refusal to carry out the
reasonable directives of Cepheid, if such failure continues for fifteen (15) days or more after Cepheid has given written notice describing such failure, provided that such notice shall be required only with respect to the first
failure.

  

	 	c.	“Change of Control” means (i) any “person” (as such term is used in Sections 13(d) and 14(d) of the Securities Exchange Act of 1934, as amended (the “Exchange
Act”)), other than a trustee or other fiduciary holding securities of Cepheid under an employee benefit plan of Cepheid, becomes the “beneficial owner” (as defined in Rule 13d-3 promulgated under the Exchange Act),
directly or indirectly, of securities of Cepheid representing 50% or more of (A) the outstanding shares of common stock of Cepheid or (B) the combined voting power of Cepheid’s then outstanding securities; (ii) Cepheid is party
to a merger or consolidation which results in the voting securities of Cepheid outstanding immediately prior thereto failing to continue to represent (either by remaining outstanding or by being converted into voting securities of the surviving or
another entity) at least 50% percent of the combined voting power of the voting securities of Cepheid or such surviving or other entity outstanding immediately after such merger or consolidation; (iii) the sale or disposition of all or
substantially all of Cepheid’s assets (or consummation of any transaction having similar effect); (iv) the dissolution or liquidation of Cepheid; or (v) individuals who, as of the Effective Date, constitute the Board of Directors (the
“Incumbent Board”) cease for any reason to constitute at least a majority of such Board of Directors; provided that any individual who becomes a director of Cepheid subsequent to the Effective Date, whose election, or
nomination for election by Cepheid shareholders, was approved by the vote of at least a majority of the directors then in office shall be deemed a member of the Incumbent Board. 

 

	 	d.	“Termination Upon Change of Control” means (i) any Termination Due to Retirement within twelve months following a Change of Control, provided that you are Cepheid’s Chief Executive Officer
on or immediately prior to the date of such Change of Control; (ii) any Termination without Cause within twelve months following a Change of Control; or (iii) any Involuntary Termination where (A) any condition constituting Good
Reason occurs within twelve months following the Change of Control, and (B) such Involuntary Termination occurs within the time periods specified in the definition of Good Reason. 

 

	 	e.	“COBRA” means the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended. 

  

	 	f.	“Disability” shall have that meaning set forth in Section 22(e)(3) of the Code. 

  
 3 

	 	9.	Separation Benefits. Upon termination of your employment with Cepheid for any reason, you will receive payment of (i) any earned but unpaid Base Salary, any earned but unpaid bonus, and any
earned but unused vacation or PTO to the extent required by law, (ii) other unpaid and then vested amounts, including any amount payable to you under the specific terms of any agreements, plans or awards in which you participate (and subject to the
terms of the foregoing), unless otherwise specifically provided in this Employment Agreement, and (iii) reimbursement for all reasonable and necessary expenses incurred by you in connection with your performance of services on behalf of Cepheid in
accordance with applicable Cepheid policies and guidelines, in each case as of the effective date of such termination of employment (the “Accrued Compensation”). Additionally, your benefits will be continued under
Cepheid’s then existing benefit plans and policies for so long as provided under the terms of such plans and policies and as required by applicable law. Under certain circumstances, you will also be entitled to receive severance benefits
as set forth below provided you timely sign a valid and binding Confidential Separation Agreement and General Release of All Claims in the form attached hereto as Exhibit A (the “Release”). No severance
benefit shall be paid until six (6) months and one day following the date of termination of your employment except as may be permitted under Section 409A of the Code. Any severance benefits you may be entitled to under this Section 9 will be
subject to applicable deductions and withholdings. You agree that, except as set forth below, you will not be entitled to any other compensation, award or damages with respect to your employment or termination.

 

	 	a.	Termination for Cause, Death or Disability, or Voluntary Termination. In the event you are subject to a Termination for Cause, in the event of your death or Disability, or in the event of your
Voluntary Termination during the Term, you will be paid only the Accrued Compensation as of the effective date of such termination of employment.

  

	 	b.	Termination Without Cause, Termination Due to Retirement or Involuntary Termination, in Each Case That is Not a Termination Upon Change of Control. In the event of your Termination without Cause or
Involuntary Termination during the Term or your Termination Due to Retirement, in each case that is not a Termination Upon Change of Control, provided that (except with respect to the Accrued Compensation) you deliver to Cepheid a signed Release and
satisfy all conditions to make the Release effective within thirty (30) days following your termination of employment, you shall be entitled to (i) your Accrued Compensation; (ii) your prorated Target Bonus for the year of termination based on the
number of months in such year worked prior to the date of termination (without regard to satisfaction of any target performance objectives) with such sum payable on the first business day after the thirtieth (30th) day following your termination of employment; (iii) a lump sum payment equal to the sum of (A) twelve (12) months of your then-current Base Salary and (B) your Target Bonus (without regard to
satisfaction of any target performance objectives), with such sum payable on the first business day after the thirtieth (30th) day following your termination of employment; (iv) one hundred
percent (100%) vesting, on the date of your termination of employment, of all then-unvested outstanding stock options, restricted stock units, shares of restricted stock and other equity-based awards issued to you by Cepheid (with any vested options
to remain exercisable until the earlier of (x) the end of the twelve (12)-month period following your termination of employment, (y) the applicable expiration date(s) of such options, or (z) the date such vested options are cancelled in connection
with a merger, consolidation or other corporate transaction in accordance with the terms of the applicable equity incentive plan(s) and award agreement(s) under which such options were granted), provided that any performance-based awards shall vest
only in accordance with the terms set forth in the applicable performance-based award agreement; and (v) provided you timely elect to continue health coverage under COBRA, reimbursement for any monthly COBRA premium payments you make in the first
twelve (12) months following your termination of employment (the “COBRA Continuation Period”), provided that the COBRA Continuation Period shall be twenty four (24) months in the case of a Termination Due to Retirement and
provided, further that if Cepheid determines in its sole discretion that it cannot provide the COBRA benefits described herein without violating applicable law (including, without limitation, Section 2716 of the Public Health Service Act), Cepheid
shall in lieu thereof provide you with a taxable lump sum payment in an amount equal to the then unreimbursed monthly COBRA premiums for the COBRA Continuation Period, which lump sum payment will be made on the first business day after the thirtieth
(30th) day following your termination of employment.

  
 4 

	 	c.	Termination Upon Change of Control. In the event of your Termination Upon Change of Control during the Term provided that (except with respect to the Accrued Compensation) you deliver to Cepheid the
signed Release and satisfy all conditions to make the Release effective within thirty (30) days following your termination of employment, you shall (in lieu of any benefits pursuant to Section 9(b)) be entitled to (i) your Accrued Compensation; (ii)
a lump sum payment equal to the sum of (A) twenty-four (24) months of your then current Base Salary and (B) two times your Target Bonus (paid at the 100% achievement level without regard to satisfaction of any target performance objectives) for the
year in which the termination occurs, with such sum payable on the first business day after the thirtieth (30th) day following your termination of employment; (iii) full vesting, on the date of
your termination of employment, of one hundred percent (100%) of all then-unvested outstanding stock options, restricted stock units, shares of restricted stock and other equity-based awards issued to you by Cepheid (with any vested options to
remain exercisable until the earlier of (x) the end of the twelve (12)-month period following your termination of employment, (y) the applicable expiration date(s) of such options, or (z) the date such vested options are cancelled in connection with
a merger, consolidation or other corporate transaction in accordance with the terms of the applicable equity incentive plan(s) and award agreement(s) under which such options were granted), provided that any performance-based awards shall vest only
in accordance with the terms set forth in the applicable performance-based award agreement; and (iv) provided you timely elect to continue health coverage under COBRA, reimbursement for any monthly COBRA premium payments you make in the twenty-four
(24)-month period following your termination of employment, provided that, if Cepheid determines in its sole discretion that it cannot provide the COBRA benefits described herein without violating applicable law (including, without limitation,
Section 2716 of the Public Health Service Act), Cepheid shall in lieu thereof provide you with a taxable lump sum payment in an amount equal to the then unreimbursed monthly COBRA premiums, which lump sum payment will be made on the first
business day after the thirtieth (30th) day following your termination of employment. 

  

	 	d.	Parachute Payments. In the event that the severance and other benefits provided for in this Agreement or otherwise payable to you (i) constitute “parachute payments” within the meaning of Section
280G of the Code, and (ii) but for this subparagraph, would be subject to the excise tax imposed by Section 4999 of the Code, then your severance benefits will be either: (a) delivered in full, or (b) delivered as to such lesser extent which
would result in no portion of such benefits being subject to excise tax under Section 4999 of the Code, whichever of the foregoing amounts, taking into account the applicable federal, state and local income taxes and the excise tax imposed by
Section 4999, results in the receipt by you on an after-tax basis, of the greatest amount of benefits, notwithstanding that all or some portion of such benefits may be taxable under Section 4999 of the Code. Unless you and Cepheid otherwise
agree in writing, any determination required under this subparagraph will be made in writing by Cepheid’s public accountants immediately prior to any change of control or such other person or entity to which the parties mutually agree (the
“Accountants”), whose determination will be conclusive and binding upon you and Cepheid for all purposes. For purposes of making the calculations required by this subparagraph, the Accountants may make reasonable
assumptions and approximations concerning applicable taxes and may rely on reasonable good faith interpretations concerning the application of Sections 280G and 4999 of the Code. You and Cepheid will furnish to the Accountants such information
and documents as the Accountants may reasonably request in order to make a determination under this subparagraph. Cepheid will bear all costs the Accountants may incur in connection with any calculations contemplated by this
subparagraph.

  

	 	e.	Mitigation. No payments due you hereunder shall be subject to mitigation or offset. 

  

	 	10.	Indemnification Agreement. The standard form of indemnification agreement for officers and directors, which you entered into with Cepheid to indemnify you against certain liabilities you may incur as
an officer or director of Cepheid shall remain in effect. 

  

	 	11.	Proprietary Information and Inventions Agreement. The standard form of Cepheid’s Proprietary Information and Inventions Agreement you entered into when you commenced employment with Cepheid shall
remain in effect. 

  
 5 

	 	12.	Nonsolicitation. If Cepheid performs its obligations to deliver the severance compensation set forth in Section 9 of this Employment Agreement, then for a period of one year after the termination of
your employment, you will not solicit any Cepheid employee to discontinue that person’s employment relationship with Cepheid. 

  

	 	13.	Arbitration. Any controversy or claim arising out of or relating this Employment Agreement, its enforcement, arbitrability, or interpretation, or because of an alleged breach, default, or
misrepresentation in connection with any of its provisions, shall be submitted to arbitration in Santa Clara County, California, or such other location as is mutually agreed between you and the Company, before three arbitrators, in accordance with
the National Rules for the Resolution of Employment Disputes then in effect of the American Arbitration Association (“AAA”) as modified by the terms and conditions of this Section; provided, however, that provisional
injunctive relief may, but need not, be sought in a court of law while arbitration proceedings are pending, and any provisional injunctive relief granted by such court shall remain effective until the matter is finally determined by the arbitrators.
The arbitrators shall be selected by mutual agreement of the parties or, if the parties cannot agree, by striking from a list of arbitrators supplied by AAA. The arbitrators shall issue a written opinion revealing, however briefly, the
essential findings and conclusions upon which the award is based. Final resolution of any dispute through arbitration may include any remedy or relief which the arbitrator deems just and equitable. Any award or relief granted by the arbitrators
hereunder shall be final and binding on the parties hereto and may be enforced by any court of competent jurisdiction. The parties acknowledge that they are hereby waiving any rights to trial by jury in any action, proceeding or counterclaim brought
by either of the parties against the other in connection with any matter whatsoever arising out of or in any way connected with this Employment Agreement. 

  

	 	14.	Section 409A. 

  

	 	a.	To the extent (i) any payments to which you become entitled under this Employment Agreement, or any agreement or plan referenced herein, in connection with your termination of employment with Cepheid constitute deferred
compensation subject to Section 409A of the Code and (ii) you are deemed at the time of such termination of employment to be a “specified” employee under Section 409A of the Code, then, notwithstanding anything herein to the contrary, such
payment or payments shall not be made or commence until the earlier of (A) the expiration of the six (6)-month period measured from the date of your “separation from service” (as such term is at the time defined in regulations under
Section 409A of the Code) with Cepheid; or (B) the date of your death following such separation from service; provided, however, that such deferral shall only be effected to the extent required to avoid adverse tax treatment to you, including
(without limitation) the additional twenty (20%) percent tax for which you would otherwise be liable under Section 409A(a)(1)(B) of the Code in the absence of such deferral. Upon the expiration of the applicable deferral period, any payments
which would have otherwise been made during that period (whether in a single sum or in installments) in the absence of this paragraph shall be paid to you or your beneficiary in one lump sum (without interest). 

 

	 	b.	Except as otherwise expressly provided herein, to the extent any expense reimbursement or the provision of any in-kind benefit under this Employment Agreement (or otherwise referenced herein) is determined to be subject
to (and not exempt from) Section 409A of the Code, the amount of any such expenses eligible for reimbursement, or the provision of any in-kind benefit, in one calendar year shall not affect the expenses eligible for reimbursement or in kind benefits
to be provided in any other calendar year, in no event shall any expenses be reimbursed after the last day of the calendar year following the calendar year in which you incurred such expenses, and in no event shall any right to reimbursement or the
provision of any in-kind benefit be subject to liquidation or exchange for another benefit. 

  
 6 

	 	c.	To the extent that any provision of this Employment Agreement is ambiguous as to its exemption or compliance with Section 409A, the provision will be read in such a manner so that all payments hereunder are exempt from
Section 409A to the maximum permissible extent, and for any payments where such construction is not tenable, that those payments comply with Section 409A to the maximum permissible extent. To the extent any payment under this Employment
Agreement may be classified as a “short-term deferral” within the meaning of Section 409A, such payment shall be deemed a short-term deferral, even if it may also qualify for an exemption from Section 409A under another provision of
Section 409A. 

  

	 	d.	Payments pursuant to this Employment Agreement (or referenced in this Employment Agreement) are intended to constitute separate payments for purposes of Section 1.409A-2(b)(2) of the regulations under Section 409A.

  

	 	15.	Clawback or Recoupment. All incentive-based compensation payable hereunder, including amounts payable under the Incentive Plan and performance-based equity awards, shall be subject to clawback or
recoupment pursuant to any compensation clawback or recoupment policy adopted by the Board of Directors or required by law during or after the term of your employment or other service to Cepheid. You agree to promptly pay to Cepheid any such amounts
required to be paid pursuant to such policy or applicable law. 

  

	 	16.	Miscellaneous. 

  

	 	a.	At-will Employment. California is an “at-will” employment state, and Cepheid is an at-will employer. This means that either you or Cepheid has the right to terminate the employment
relationship at any time with or without cause. 

  

	 	b.	Absence of Conflicts. You represent that upon the Effective Date your performance of your duties under this Employment Agreement will not breach any other agreement as to which you are a party.

  

	 	c.	Attorneys Fees. If a legal action or other proceeding is brought for enforcement of this Employment Agreement because of an alleged dispute, breach, default, or misrepresentation in connection with any of
the provisions of this Employment Agreement, the successful or prevailing party shall be entitled to recover reasonable attorneys’ fees and costs incurred, both before and after judgment, in addition to any other relief to which they may be
entitled. 

  

	 	d.	Successors. This Employment Agreement is binding on and may be enforced by Cepheid and its successors and assigns and is binding on and may be enforced by you and your heirs and legal
representatives. Cepheid will require any successor or assign (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business and/or assets of Cepheid, expressly, absolutely and
unconditionally to assume and agree to perform this Employment Agreement in the same manner and to the same extent that Cepheid would be required to perform it if no such succession or assignment had taken place. 

 

	 	e.	Notices. Notices under this Employment Agreement must be in writing and will be deemed to have been given when personally delivered or delivered by national overnight courier service or two days after mailed
by U.S. registered or certified mail, return receipt requested and postage prepaid. Mailed notices to you will be addressed to you at the home address which you have most recently communicated to Cepheid in writing. Notices to Cepheid will
be addressed to its General Counsel at Cepheid’s corporate headquarters. 

  

	 	f.	Waiver. No provision of this Employment Agreement will be modified or waived except in writing signed by you and an officer of Cepheid duly authorized by its Board of Directors. No waiver by either
party of any breach of this Employment Agreement by the other party will be considered a waiver of any other breach of this Employment Agreement. 

  

	 	g.	Entire Agreement. This Employment Agreement represents the entire agreement between us concerning the subject matter of your employment by Cepheid and supersedes in full the terms of the Prior Agreement,
except as provided herein. 

  
 7 

	 	h.	Governing Law. This Employment Agreement will be governed by the laws of the State of California without reference to conflict of laws provisions. 

  
 8 

 John, we are very pleased to extend this Employment Agreement to you. Please indicate your acceptance of the
terms of this Employment Agreement by signing in the place indicated below. 
  

					
	 Very truly yours,
	 		 	
			
	 Hollings C. Renton
	 		 	
	Chairman, Compensation and Organizational Development Committee	 		 	
	 Cepheid Board of Directors
	 		 	
			
	 For Cepheid:
	 		 	
			
	 /s/ Daniel Madden
	 	Date:	 	7/27/16
	 Daniel Madden

Executive Vice President and Chief Financial Officer
	 		 	
	 Cepheid
	 		 	
			
	 1 accept the terms of this Employment Agreement:
	 		 	
			
	 /s/ John L. Bishop
	 	 Date:
	 	 7/27/16

	 John L. Bishop
	 		 	

  
 9 

 EXHIBIT A 

CONFIDENTIAL SEPARATION AGREEMENT AND 

GENERAL RELEASE OF ALL CLAIMS 

In consideration of the termination benefits described herein (the “Benefits”) provided and to be provided to me by Cepheid,
or any successor thereof (“Cepheid”) pursuant to my Employment Agreement with Cepheid dated as of July 26, 2016 (the “Agreement”) and in connection with the termination of my employment, I agree to the
following general release (the “Release”). The Release shall in no way abridge my rights to full and complete payment of the Benefits and the Release shall be void absent full payment of the Benefits. 

1. On behalf of myself, my heirs, executors, administrators, successors, and assigns, I hereby fully and forever generally release and
discharge Cepheid, its current, former and future parents, subsidiaries, affiliated companies, related entities, employee benefit plans, and their fiduciaries, predecessors, successors, officers, directors, shareholders, agents, employees and
assigns (collectively, the “Company”) from any and all claims, causes of action, and liabilities up through the date of my execution of the Release. The claims subject to this release include, but are not limited to, those
relating to my employment with Company and/or any predecessor to Company and the termination of such employment. All such claims (including related attorneys’ fees and costs) are barred without regard to whether those claims are based on
any alleged breach of a duty arising in statute, contract, or tort. This expressly includes waiver and release of any rights and claims arising under any and all laws, rules, regulations, and ordinances, including, but not limited to: Title VII
of the Civil Rights Act of 1964; the Older Workers Benefit Protection Act; the Americans With Disabilities Act; the Age Discrimination in Employment Act; the Fair Labor Standards Act; the National Labor Relations Act; the Family and Medical Leave
Act; the Employee Retirement Income Security Act of 1974, as amended (“ERISA”); the Workers Adjustment and Retraining Notification Act; the California Fair Employment and Housing Act (if applicable); the provisions of the California
Labor Code (if applicable); the Equal Pay Act of 1963; and any similar law of any other state or governmental entity. The parties agree to apply California law in interpreting the Release. Accordingly, I further waive any rights under
Section 1542 of the Civil Code of the State of California or any similar state statute. Section 1542 states: “A general release does not extend to claims which the creditor does not know or suspect to exist in his or her favor at the
time of executing the release, which, if known to him or her, must have materially affected his or her settlement with the debtor.”

2. In understanding the terms of the Release and my rights, I have been advised to consult with an attorney of my choice prior to executing
the Release. I understand that nothing in the Release shall prohibit me from exercising legal rights that are, as a matter of law, not subject to waiver such as: (a) my rights under applicable workers’ compensation laws; (b) my right, if
any, to seek unemployment benefits; (c) my right to indemnity under California Labor Code Section 2802, Section 317 of the California Corporations Code or other applicable state-law right to indemnity (in each case, such statutory rights shall be
subject to the terms and conditions of the Company’s by-laws and other indemnification provisions); and (d) my right to file a charge or complaint with a government agency such as but not limited to the Equal Employment Opportunity Commission,
the National Labor Relations Board, the Department of Labor, the California Department of Fair Employment and Housing, or other applicable state agency. Moreover, I will continue to be indemnified for my actions taken while employed by the
Company to the same extent as other then-current or former directors and officers of the Company under the Company’s Certificate of Incorporation and by-laws and the Director and Officer Indemnification Agreement between me and the Company, if
any, or any contractual arrangements between me and the Company providing for rights to indemnification and I will continue to be covered by the Company’s directors and officers liability insurance policy as in effect from time to time to the
same extent as other then-current or former directors and officers of the Company, each subject to the requirements of the laws of the State of Delaware. To the fullest extent permitted by law, any dispute regarding the scope of this general
release shall be resolved through binding arbitration as set forth below, and the arbitration provision set forth in my Agreement. 
 3. I
understand and agree that Company will not provide me with the Benefits unless I execute the Release. I also understand that I have received or will receive, regardless of the execution of the Release, all wages owed to me together with any
accrued but unused vacation pay, less applicable withholdings and deductions, earned through my termination date. 

 4. As part of my existing and continuing obligations to Company, I have returned to Company all
Company documents (and all copies thereof) and other Company property that I have had in my possession at any time, including but not limited to Company files, notes, drawings, records, business plans and forecasts, financial information,
specification, computer-recorded information, tangible property (including, but not limited to, computers, laptops, pagers, etc.), credit cards, entry cards, identification badges and keys; and any materials of any kind which contain or embody any
proprietary or confidential information of Company (and all reproductions thereof). I understand that, even if I did not sign the Release, I am still bound by any and all confidential/proprietary/trade secret information, non-disclosure and
inventions assignment agreement(s) signed by me in connection with my employment with Company, or with a predecessor or successor of Company pursuant to the terms of such agreement(s). 

5. I represent and warrant that I am the sole owner of all claims relating to my employment with Company and/or with any predecessor of
Company, and that I have not assigned or transferred any claims relating to my employment to any other person or entity. 
 6. I agree to
keep the Benefits and the provisions of the Release confidential and not to reveal its contents to anyone except my lawyer, my spouse or other immediate family member, and/or my financial consultant, or as required by legal process or applicable
law. 
 7. I understand and agree that the Release shall not be construed at any time as an admission of liability or wrongdoing by either
Company or myself. 
 8. I agree that for a period of one year following my termination of employment, I will not make any negative or
disparaging statements or comments, either as fact or as opinion, about Company, its employees, officers, directors, shareholders, vendors, products or services, business, technologies, market position or performance. For a period of one year
following my termination of employment, Company (including its subsidiaries and affiliates) will not make, and agrees to use its reasonable best efforts to cause the officers, directors and spokespersons of the Company to refrain from making, any
negative or disparaging statements or comments, either as fact or as opinion, about me (or authorizing any statements or comments to be reported as being attributed to the Company). Nothing in this paragraph shall prohibit me or Company from
providing truthful information in response to a subpoena or other legal process. 
 9. Any controversy or claim arising out of or relating
this Release, its enforcement, arbitrability, or interpretation, or because of an alleged breach, default, or misrepresentation in connection with any of its provisions, shall be submitted to arbitration in Santa Clara County, California, or such
other location as is mutually agreed between me and the Company, before three arbitrators, in accordance with the National Rules for the Resolution of Employment Disputes then in effect of the American Arbitration Association
(“AAA”) as modified by the terms and conditions of this Section; provided, however, that provisional injunctive relief may, but need not, be sought in a court of law while arbitration proceedings are pending, and any
provisional injunctive relief granted by such court shall remain effective until the matter is finally determined by the arbitrators. The arbitrators shall be selected by mutual agreement of the parties or, if the parties cannot agree, by striking
from a list of arbitrators supplied by AAA. The arbitrators shall issue a written opinion revealing, however briefly, the essential findings and conclusions upon which the award is based. Final resolution of any dispute through arbitration may
include any remedy or relief which the arbitrator deems just and equitable. Any award or relief granted by the arbitrators hereunder shall be final and binding on the parties hereto and may be enforced by any court of competent jurisdiction. The
parties acknowledge that they are hereby waiving any rights to trial by jury in any action, proceeding or counterclaim brought by either of the parties against the other in connection with any matter whatsoever arising out of or in any way connected
with this Release. 
 10. I agree that I have had at least twenty-one (21) calendar days in which to consider whether to execute the
Release, no one hurried me into executing the Release during that period, and no one coerced me into executing the Release. I understand that the offer of the Benefits and the Release shall expire on the twenty-second (22nd) calendar day after my employment termination date if I have not accepted it by that time. I further understand that Company’s obligations under the Release shall not become effective or
enforceable until the eighth (8th) calendar day after the date I sign the Release provided that I have timely delivered it to Company (the “Effective Date”) and that in the seven
(7) day period following the date I deliver a signed copy of the Release to Company I understand that I may revoke my acceptance of the Release. I understand that the Benefits will become available to me at such time after the Effective Date.

  
 2 

 11. In executing the Release, I acknowledge that I have not relied upon any statement made by
Company, or any of its representatives or employees, with regard to the Release unless the representation is specifically included herein. Furthermore, the Release contains our entire understanding regarding eligibility for Benefits and
supersedes any or all prior representation and agreement regarding the subject matter of the Release. However, the Release does not modify, amend or supersede written Company agreements that are consistent with enforceable provisions of this
Release such as my Agreement, proprietary information and invention assignment agreement, and any stock, stock option and/or stock purchase agreements between Company and me. Once effective and enforceable, this agreement can only be changed by
another written agreement signed by me and an authorized representative of Company. 
 12. Should any provision of the Release be
determined by an arbitrator, court of competent jurisdiction, or government agency to be wholly or partially invalid or unenforceable, the legality, validity and enforceability of the remaining parts, terms, or provisions are intended to remain in
full force and effect. Specifically, should a court, arbitrator, or agency conclude that a particular claim may not be released as a matter of law, it is the intention of the parties that the general release and the waiver of unknown claims above
shall otherwise remain effective to release any and all other claims. I acknowledge that I have obtained sufficient information to intelligently exercise my own judgment regarding the terms of the Release before executing the Release. 

13. The Benefits provided and to be provided to me by the Company consist of the benefits and payments in accordance with Section 9 of the
Agreement. 
 14. This Release will be construed in accordance with, and governed by the laws of the State of California. 

[SIGNATURE PAGE TO GENERAL RELEASE AGREEMENT
FOLLOWS] 

  
 3 

 EMPLOYEE’S ACCEPTANCE OF RELEASE 

BEFORE SIGNING MY NAME TO THE RELEASE, I STATE THE FOLLOWING: I HAVE READ THE RELEASE, I UNDERSTAND IT AND I KNOW THAT I AM GIVING UP IMPORTANT
RIGHTS. I HAVE OBTAINED SUFFICIENT INFORMATION TO INTELLIGENTLY EXERCISE MY OWN JUDGMENT. I HAVE BEEN ADVISED THAT I SHOULD CONSULT WITH AN ATTORNEY BEFORE SIGNING IT, AND I HAVE SIGNED THE RELEASE KNOWINGLY AND VOLUNTARILY. 

EFFECTIVE UPON EXECUTION BY EMPLOYEE AND THE COMPANY. 
  

					
		 	Date delivered to employee             ,             .
		
		 	Executed this              day of             ,
            .
		 	
		 		 	  

		 		 	John L. Bishop

  

	
	 Agreed and Accepted:

	
	 CEPHEID

	
	  

	 By:

	 Date:

 [SIGNATURE PAGE TO GENERAL
RELEASE AGREEMENT]Exhibit 10.1

 

Execution Copy

 

STEADYMED LTD.

 

SUBSCRIPTION AGREEMENT

 

Restricted Ordinary Shares 
 and Warrants to purchase Restricted Ordinary Shares

 

STEADYMED LTD., an Israeli incorporated company (the “Company”), is offering for sale an aggregate of up to $32,000,000 of (i) its restricted ordinary shares (the “Shares”), and (ii) warrants (the “Warrants”), in the form attached hereto as Exhibit A, to purchase a number of restricted ordinary shares of the Company equal to 100 percent of the total number of Shares sold in the Initial Closing (as defined below) (the “Warrant Shares”), to persons who qualify as “accredited investors,” as such term is defined in Rule 501(a) of Regulation D of the Securities Act of 1933, as amended (the “Securities Act”), at the applicable Price (as defined below) per Share and, if applicable, associated Warrant (the “Offering”). The undersigned (individually and/or collectively, the “Participant”) hereby applies to purchase Shares and Warrants in accordance with the terms and conditions of this Subscription Agreement (the “Agreement”). The Shares and Warrants together shall hereafter be referred to as the “Securities.”

 

AGREEMENT

 

In consideration of the mutual covenants contained in this Agreement and for other good and valuable consideration, the receipt of which is hereby acknowledged, the Company and each Participant (severally and not jointly) hereby agree as follows:

 

SECTION 1.        AUTHORIZATION OF SALE OF THE SECURITIES. Subject to the terms and conditions of this Agreement, the Company has or before the Initial Closing will have authorized the sale and issuance of up to $32,000,000 of (i) ordinary shares of the Company, nominal value NIS $0.01 per share and (ii) warrants to purchase a number of ordinary shares of the Company equal to the number of Shares purchased in the Initial Closing hereunder, at an exercise price per share equal to 115% of the Initial Price (as defined below). Such Warrants shall be issued in substantially the form attached hereto as Exhibit A.

 

SECTION 2.        AGREEMENT TO SELL AND PURCHASE THE SECURITIES. The Company shall issue and sell to each Participant, severally and not jointly, and each Participant shall purchase from the Company, severally and not jointly, (1) in the Initial Closing, the number of Shares and a Warrant, both as set forth on such Participant’s signature page attached at the end of this Agreement (the “Signature Page”), at a purchase price of $3.13 per Share (the “Initial Price”) and $0.125 per Warrant Share and (2) in the Second Closing (as defined below), the number of Shares equal to the excess of the Total Subscription Amount (set forth on the Signature Page) over the Aggregate Purchase Price in the Initial Closing (set forth on the Signature Page), divided by the higher of (i) the Initial Price or (ii) the average closing price of the Company’s ordinary shares on the NASDAQ Market (as defined below) over the 30 trading days immediately preceding the Milestone Date (as defined below) (the “Second Price,” and with the Initial Price, each a “Price”) rounded down to the nearest whole number, at a purchase price per Share equal to the Second Price (for each Closing, subject to proportionate adjustment upon the occurrence of any stock split, stock dividend, reverse stock split or like event that is consummated or becomes effective during the period commencing on the date hereof and ending

 

1

 

immediately prior to each Closing). Subject to each Participant’s termination right pursuant to Section 8, the purchase of Shares and Warrants hereunder (the “Subscription”) shall be irrevocable by the Participant, not transferable or assignable by the Participant and may be rejected in whole or in part by the Company in its sole discretion. In the event the Subscription is rejected by the Company or this Agreement is terminated in accordance with its terms, all funds and documents tendered by the Participant shall be returned to such Participant and terminated, as applicable.

 

SECTION 3.        CLOSING AND DELIVERY

 

3.1          Closing. The first tranche of this Offering is scheduled to close (the “Initial Closing”) August 3, 2016 at 10:00 A.M. Pacific Time. The target Offering is for up to $32,000,000 of Securities, provided that the proceeds from the Initial Closing shall not be less than $21,333,000.

 

3.2          Delivery of the Shares and Warrants. At each Closing, the Company will (i) issue to its transfer agent an instruction letter instructing the transfer agent to record in book entry form, or upon request deliver a share certificate evidencing, the Shares purchased hereunder to the Participant within three days of such instruction and (ii) with respect only to the Initial Closing, issue and deliver a Warrant exercisable for the number of restricted ordinary shares of the Company specified on the signature page hereof, against payment of the purchase price therefor by check or wire transfer. The Company shall also deliver an executed copy of this Agreement to each Participant.

 

3.3          Subsequent Closing. At any time during 14 days following the Milestone Date, the Company may at its election, trigger a second closing by notifying each Participant of the achievement of the Milestones (as defined below) (the “Call Notice”), in which event, the second closing with each Purchaser shall take place within ten (10) business days following the date the Call Notice was sent by the Company to the Participants (the “Second Closing,” and together with the Initial Closing, the “Closings” and individually, a “Closing”). The Company’s right to trigger the Second Closing will terminate if the Call Notice is not sent by September 30, 2017. Subscriptions in each Closing shall be made on the terms and conditions set forth in this Agreement, and (i) the representations and warranties of the Company set forth in Section 4 hereof shall speak as of the Initial Closing and the Company shall have no obligation to update any such disclosure, and (ii) the representations and warranties of the Participants in Section 5 hereof shall speak as of each Closing. The “Milestone Date” shall be later of: (i) the date that the Company’s New Drug Application for Trevyent is accepted by the U.S. Food and Drug Administration and (ii) the date the Patent Trial and Appeal Board issues a final written decision invalidating the challenged claims related and relevant to Trevyent, under the Company’s Inter Partes Review under case number IPR2016-00006 (together the “Milestones”). For greater clarity, the Company shall have no obligation to deliver the Call Notice and trigger the Second Closing even if the Milestones occurs.

 

SECTION 4.        REPRESENTATIONS, WARRANTIES AND COVENANTS OF THE COMPANY.

 

Subject to and except as set forth on the Schedule of Exceptions which is arranged in sections corresponding to the sub-section numbered provisions contained below in this Section and except as described in the SEC Reports (as defined below), the Company hereby represents and warrants to, and covenants with, the Participants as of the date of the Initial Closing and the Second Closing as follows:

 

2

 

4.1          Organization and Qualification. The Company is an Israeli incorporated company duly organized, validly existing and in good standing under the laws of Israel and has all requisite corporate power and authority and all licenses, permits and authorizations to conduct its business as it is currently being conducted and as it is presently proposed to be conducted and to own, lease and operate its properties. A true and complete copy of the Tenth Amended and Restated Articles of Association of the Company (the “Articles”), as amended to and as in effect on the date hereof, has been filed with the SEC as Exhibit 3.2 to the Company’s Registration Statement on Form S-1 (File No. 333-201949) on March 9, 2015. The Company is duly qualified and is authorized to transact business and is in good standing as a foreign corporation in each jurisdiction in which the failure so to qualify would have a Material Adverse Effect. As used in this Agreement, a “Material Adverse Effect” means (a) a material adverse effect upon the business, operations, properties, assets or condition (financial or otherwise) of the Company or, as the case may be, the Company and any of its subsidiaries, taken as a whole, (b) the impairment of the ability of the Company to perform its obligations under this Agreement or (c) a material adverse effect on the legality, validity or enforceability of this Agreement, provided, however, that for purposes of determining whether there shall have been any such “Material Adverse Effect”, (i) any adverse change resulting from or relating to worldwide general business or economic conditions shall be disregarded, (ii) any adverse change resulting from or relating to conditions generally affecting the industry in which the Company competes shall be disregarded, and (iii) any adverse change to the stock price of the Company’s ordinary shares, as quoted on any nationally recognized stock quotation system, shall be disregarded, but, in the case of (i), (ii) and (iii), only to the extent that such changes do not have a disproportionate impact on the Company relative to other companies in its industry.

 

4.2          Due Execution, Delivery and Performance. Assuming and relying on the accuracy of the representation set forth in Section 5, the Company’s execution, delivery and performance of this Agreement and the issuance and sale of the Shares and Warrants have been duly authorized by all requisite corporate and shareholder action by the Company and its shareholders, respectively. Upon the execution and delivery by the Company, and assuming the valid execution and delivery of this Agreement by each of the Participants, this Agreement will constitute the valid and binding obligation of the Company, enforceable in accordance with its terms, except as enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors’ and contracting parties’ rights generally and except as enforceability may be subject to general principles of equity (regardless of whether such enforceability is considered in a proceeding in equity or at law), including specific performance, and except as the indemnification provisions contained in Section 9.4 hereof may be legally unenforceable.

 

4.3          No Conflicts. The Company’s execution, delivery and performance of this Agreement and the issuance of the Shares and Warrants will not violate, conflict with, result in a breach of or constitute (upon notice or lapse of time or both) a default under, or result in the creation or imposition of any lien, security interest, mortgage, pledge, charge or other encumbrance upon any properties or assets of the Company under any (a) law, regulation, rule, injunction, judgment, order, decree, ruling, charge or other restriction of any government, governmental agency, court or arbitrator to which the Company is subject, (b) the Company’s Articles bylaws or other organizational documents or (c) any provision of any indenture, mortgage, agreement, contract or other instrument to which the Company is a party or by which the Company or any of its properties or assets is bound as of the date hereof, except in the case

 

3

 

of each of clauses (a) and (c), such as could not have or reasonably be expected to result in a Material Adverse Effect.

 

4.4          Governmental Consents. Except for applicable filings with The NASDAQ Stock Market LLC (the “Nasdaq Market”), under the Securities Act or the Securities Exchange Act of 1934, as amended (the “Exchange Act”), no consent, approval, qualification, order or authorization of, or filing with, any local, state, or federal governmental authority is required on the part of the Company in connection with the Company’s valid execution, delivery, or performance of this Agreement, or the offer, sale or issuance of the Shares and Warrants by the Company, other than any post-closing filings as may be required under applicable federal, state or Israeli securities laws, which will be timely filed within the applicable periods therefor.

 

4.5          Issuance and Subscription of the Securities. When issued and paid for in accordance with this Agreement, the Shares and Warrants to be subscribed for hereunder by the Participants and, upon exercise of the Warrants in accordance with their terms, the Warrant Shares will be validly issued and outstanding, fully paid and non-assessable. The Company has reserved from its duly authorized capital stock the maximum number of shares for issuance of all Shares and all shares underlying the Warrants.

 

4.6          SEC Reports.

 

(a)           Since March 19, 2015, the Company has filed in a timely manner with the Securities and Exchange Commission (the “SEC”) all reports (“SEC Reports”) required to be filed by it under the Exchange Act. All of the SEC Reports filed by the Company comply in all material respects with the requirements of the Exchange Act. None of the SEC Reports contains, as of the respective dates thereof, any untrue statement of a material fact or omits to state any material fact required to be stated therein or necessary to make the statements therein not misleading in light of the circumstances under which they were made. All financial statements contained in the SEC Reports (i) comply in all material respects with applicable accounting requirements and the rules and regulations of the SEC with respect thereto as in effect at the time of filing and (ii) have been prepared in accordance with generally accepted accounting principles consistently applied throughout the period indicated (“GAAP”). Each balance sheet is in accordance with the books and records of the Company and presents fairly in accordance with GAAP the financial position of the Company as of the date of such balance sheet, and each statement of operations, of shareholders’ equity and of cash flows is in accordance with the books and records of the Company and presents fairly in accordance with GAAP the results of operations, the shareholders’ equity and the cash flows of the Company for the periods then ended. The Company has never been an issuer subject to Rule 144(i) under the Securities Act.

 

(b)           No event has occurred since March 31, 2016, requiring the filing of an SEC Report that has not heretofore been filed and furnished to the Participants (including, without limitation, any amendment to any such SEC Report).

 

4.7          No Material Change. Since the date of the latest audited financial statements included within the SEC Reports, and except as otherwise reported in the SEC Reports, (i) there has been no event, occurrence or development that has had or that would reasonably be expected to result in a Material Adverse Effect, (ii) the Company has not incurred any liabilities (contingent or otherwise) other than (A) trade payables and accrued expenses incurred in the ordinary course of business consistent with past practice and (B) liabilities not required to be reflected in the Company’s financial statements pursuant to GAAP or disclosed in filings made

 

4

 

with the SEC, (iii) the Company has not altered its method of accounting, (iv) the Company has not declared or made any dividend or distribution of cash or other property to its stockholders or purchased, redeemed or made any agreements to purchase or redeem any shares of its capital stock and (v) the Company has not issued any equity securities to any officer, director or affiliate, except pursuant to existing Company stock option plans. Except as may be set forth in the SEC Reports, the Company does not have pending before the SEC any request for confidential treatment of information. Except for the issuance of the Securities contemplated by this Agreement, no event, liability, fact, circumstance, occurrence or development has occurred or exists or is reasonably expected to occur or exist with respect to the Company or its business, properties, operations, assets or financial condition that would be required to be disclosed by the Company under applicable securities laws at the time this representation is made or deemed made that has not been publicly disclosed on or prior to the date that this representation is made.

 

4.8          Executive Officers. As of the date hereof, and since the date of the most recent SEC Report, there have been no resignations, terminations or appointments with respect to (a) the Board of Directors of the Company or (b) the executive officers of the Company.

 

4.9          Capitalization. The authorized share capital of the Company consists of 50,000,000 shares of ordinary shares, nominal value NIS $0.01 per share, of which 13,585,810 such shares were issued and outstanding as of July 28, 2016. Except as contemplated by this Agreement and except for shares reserved under the Company’s Amended and Restated 2009 Stock Incentive Plan, 2013 Stock Incentive Subplan and Warrant to purchase 10,191 ordinary shares, as of July 28, 2016, there are no existing options, warrants, calls, preemptive (or similar) rights, subscriptions or other rights, agreements, arrangements or commitments of any character obligating the Company to issue, transfer or sell, or cause to be issued, transferred or sold, any shares of share capital of the Company or other equity interests in the Company or any securities convertible into or exchangeable for such shares of share capital or other equity interests, and there are no outstanding contractual obligations of the Company to repurchase, redeem or otherwise acquire, or prepare and file with the SEC any registration statement to register under the Securities Act with respect to, any such shares of share capital or other equity interests. There exist no statutory preemptive, or other similar rights to purchase securities of the Company.

 

4.10        Nasdaq Compliance. The Company’s ordinary shares are registered pursuant to Section 12(b) of the Exchange Act and is listed on the NASDAQ Global Market (“Nasdaq Stock Market”), and the Company has taken no action designed to, or which to its knowledge is likely to have the effect of, terminating the registration of its ordinary shares under the Exchange Act or delisting its ordinary shares from the Nasdaq Stock Market.

 

4.11        Litigation. There is no action, suit, inquiry, notice of violation, proceeding or investigation pending or, to the knowledge of the Company, threatened against or affecting the Company or any of its properties before or by any court, arbitrator, governmental or administrative agency or regulatory authority (federal, state, county, local or foreign) (collectively, an “Action”) which (i) adversely affects or challenges the legality, validity or enforceability of this Agreement or the Securities or (ii) would, if there were an unfavorable decision, have or reasonably be expected to result in a Material Adverse Effect. Neither the Company nor any director or officer thereof, is or has been the subject of any Action involving a claim of violation of or liability under federal or state securities laws or a claim of breach of fiduciary duty. There has not been, and to the knowledge of the Company, there is not pending or contemplated, any investigation by the SEC involving the Company or any current or former director or officer of the Company. The SEC has not issued any stop order or other order

 

5

 

suspending the effectiveness of any registration statement filed by the Company under the Exchange Act or the Securities Act.

 

4.12        Compliance. The Company: (i) is not in default under or in violation of (and no event has occurred that has not been waived that, with notice or lapse of time or both, would result in a default by the Company), nor has the Company received notice of a claim that it is in default under or that it is in violation of, any indenture, loan or credit agreement or any other agreement or instrument to which it is a party or by which it or any of its properties is bound (whether or not such default or violation has been waived), (ii) is not in violation of any judgment, decree or order of any court, arbitrator or other governmental authority and (iii) is not or has not been in violation of any statute, rule, ordinance or regulation of any governmental authority, including without limitation all foreign, federal, state and local laws relating to taxes, environmental protection, occupational health and safety, product quality and safety and employment and labor matters, except in each case as would not have or reasonably be expected to result in a Material Adverse Effect.

 

4.13        Intellectual Property. The Company has, or has rights to use, all (i) all inventions (whether patentable or unpatentable, and whether or not reduced to practice), all improvements thereto, and all patents, patent applications, and patent disclosures, together with all reissuances, continuations, continuations-in-part, revisions, extensions, and reexaminations thereof, (ii) all trademarks, service marks, trade dress, logos, trade names and corporate names, together with all translations, adaptations, derivations and combinations thereof and including all goodwill associated therewith, and all applications, registrations and renewals in connection therewith, (iii) all copyrightable works, all copyrights, all applications, registrations and renewals in connection therewith, (iv) all trade secrets and confidential business information (including, without limitation, ideas, research and development, know-how, formulas, compositions, manufacturing and production processes and techniques, technical data, designs, drawings, specifications, supplier lists, and business and marketing plans and proposals), (v) all gene sequences, cell lines, chemical compounds, assays and biological materials, (vi) all other proprietary rights and (vii) all copies and tangible embodiments of any of the foregoing (in whatever form or medium) and other intellectual property rights and similar rights necessary or required for use in connection with its business as described in the SEC Reports and which the failure to so have would reasonably be expected to have a Material Adverse Effect (collectively, the “Intellectual Property Rights”). The Company has not received a notice (written or otherwise) that any of, the Intellectual Property Rights has expired, terminated or been abandoned, or is expected to expire or terminate or be abandoned, within two (2) years from the date of this Agreement except as would not reasonably be expected to have a Material Adverse Effect. The Company has not received, since the date of the latest audited financial statements included within the SEC Reports, a written notice of a claim or otherwise has any knowledge that the Intellectual Property Rights violate or infringe upon the rights of any person, except as would not have or reasonably be expected to not have a Material Adverse Effect. To the knowledge of the Company, all such Intellectual Property Rights are enforceable and there is no existing infringement by another person of any of the Intellectual Property Rights. The Company has taken reasonable security measures to protect the secrecy, confidentiality and value of all of their intellectual properties, except where failure to do so would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.

 

4.14        Transactions With Affiliates and Employees. Except as set forth in the SEC Reports, none of the officers or directors of the Company and, to the knowledge of the Company,

 

6

 

none of the employees of the Company is presently a party to any transaction with the Company (other than for services as employees, officers and directors), including any contract, agreement or other arrangement providing for the furnishing of services to or by, providing for rental of real or personal property to or from, providing for the borrowing of money from or lending of money to or otherwise requiring payments to or from any officer, director or such employee or, to the knowledge of the Company, any entity in which any officer, director, or any such employee has a substantial interest or is an officer, director, trustee, stockholder, member or partner, in each case in excess of $120,000 other than for (i) payment of salary or consulting fees for services rendered, (ii) reimbursement for expenses incurred on behalf of the Company and (iii) other employee benefits, including stock option agreements under any stock or equity incentive plan of the Company.

 

4.15        Internal Accounting Controls. The Company has implemented internal controls, which, at a minimum, are adequate to provide reasonable assurances that: (A) transactions are executed in accordance with management’s general or specific authorization; (B) transactions are recorded as necessary to: (i) permit preparation of financial statements in conformity with generally accepted accounting principles or any other criteria applicable to such statements and (ii) maintain accountability for assets; (C) access to assets is permitted only in accordance with management’s general or specific authorization; and (D) the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences. The Company is not being, and have not been, investigated by any governmental authority with respect to, or been given notice by a governmental authority of, any potential violation by the Company of any law concerning corrupting payments.

 

4.16        Registration Rights. No person has any right to cause the Company to effect the registration under the Securities Act of any securities of the Company, except as listed on Schedule 1 hereto.

 

4.17        Application of Takeover Protections. The Company and the Board of Directors have taken all necessary action, if any, in order to render inapplicable any control share acquisition, business combination, poison pill (including any distribution under a rights agreement) or other similar anti takeover provision under the Company’s certificate of incorporation (or similar charter documents) or the laws of its state of incorporation that is or could become applicable to the Participants as a result of the Participants and the Company fulfilling their obligations or exercising their rights under this Agreement, including without limitation as a result of the Company’s issuance of the Securities and the Participants’ ownership of the Securities.

 

4.18        Disclosure. Except with respect to the material terms and conditions of the transactions contemplated by this Agreement, the Company confirms that neither it nor any other person acting on its behalf has provided any of the Participants or their agents or counsel with any information that it believes constitutes or might constitute material, non-public information. The Company understands and confirms that the Participants will rely on the foregoing representation in effecting transactions in securities of the Company. All of the disclosure furnished by or on behalf of the Company to the Participants regarding the Company, its business and the transactions contemplated hereby, is true and correct in all material respects as of the date made and does not contain any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements made therein, in light of the circumstances under which they were made, not misleading. The SEC Reports disseminated by the Company during the twelve months preceding the date of this Agreement taken as a whole do

 

7

 

not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were made and when made, not misleading. The Company acknowledges and agrees that no Participants makes or has made any representations or warranties with respect to the transactions contemplated hereby other than those specifically set forth in Section 5 hereof.

 

4.19        No Integrated Offering. Assuming the accuracy of the Participants’ representations and warranties set forth in Section 5, neither the Company, nor any of its affiliates, nor any person acting on its or their behalf has, directly or indirectly, made any offers or sales of any security or solicited any offers to buy any security, under circumstances that would cause this offering of the Securities to be integrated with prior offerings by the Company for purposes of (i) the Securities Act which would require the registration of any securities under the Securities Act, or (ii) any applicable shareholder approval provisions of any trading market on which any of the securities of the Company are listed or designated.

 

4.20        Tax Status/CFC/PFIC. All taxes (whether or not shown on any tax return) for which the Company may be liable have been timely paid, and all tax returns required to have been filed by or with respect to the Company have been timely filed, unless failure to so pay or file would not have a Material Adverse Effect. The Company is treated as a corporation for federal income tax purposes. As of December 2015, the Company was not a “controlled foreign corporation” or “CFC” (as defined in Section 957 of the Internal Revenue Code of 1986, as amended (the “Code”)), and was not a “passive foreign investment company” or “PFIC” (as defined in section 1297 of the Code).

 

4.21        Foreign Corrupt Practices. The Company has complied in all material respects with laws concerning bribery, corruption, kickbacks or other similar payments or transfers of value to or from another person to obtain or retain business or secure an improper advantage. Neither the Company nor any of the Company’s directors, officers, employees or agents have, directly or indirectly, made, offered, promised or authorized any payment or gift of any money or anything of value to or for the benefit of any “foreign official” (as such term is defined in the U.S. Foreign Corrupt Practices Act of 1977, as amended (the “FCPA”)), foreign political party or official thereof or candidate for foreign political office for the purpose of (i) influencing any official act or decision of such official, party or candidate, (ii) inducing such official, party or candidate to use his, her or its influence to affect any act or decision of a foreign governmental authority, or (iii) securing any improper advantage, in the case of (i), (ii) and (iii) above, in order to assist the Company or any of its affiliates in obtaining or retaining business for or with, or directing business to, any person. Neither the Company nor any of its directors, officers, employees or agents have made or authorized any bribe, rebate, payoff, influence payment, kickback or other unlawful payment of funds or received or retained any funds in violation of any law, rule or regulation. The Company further represents that it has maintained, and has caused each of its subsidiaries and affiliates to maintain, systems of internal controls (including, but not limited to, accounting systems, purchasing systems and billing systems) to ensure compliance with the FCPA or any other applicable anti-bribery or anti-corruption law. Neither the Company, or, to the Company’s knowledge, any of its officers, directors or employees are the subject of any allegation, voluntary disclosure, investigation, prosecution or other enforcement action related to the FCPA or any other applicable foreign or domestic anti-corruption law (collectively, “Enforcement Action”). No directors, officers, employees, agents, or representatives of the Company has been an official of any governmental authority or of any

 

8

 

agency thereof, an official of a political party, or a candidate for political office. No contributions have been made by the Company, directly or indirectly, to a political party or candidate.

 

4.22        Acknowledgment Regarding Participants’ Purchase of Securities. The Company acknowledges and agrees that each of the Participants is acting solely in the capacity of an arm’s length Participant with respect to this Agreement and the transactions contemplated hereby. The Company further acknowledges that no Participant is acting as a financial advisor or fiduciary of the Company (or in any similar capacity) with respect to this Agreement and the transactions contemplated hereby and any advice given by any Participant or any of their respective representatives or agents in connection with this Agreement and the transactions contemplated hereby is merely incidental to the Participants’ purchase of the Securities. The Company further represents to each Participant that the Company’s decision to enter into this Agreement has been based solely on the independent evaluation of the transactions contemplated hereby by the Company and its representatives.

 

4.23        Acknowledgement Regarding Participant’s Trading Activity. Anything in this Agreement or elsewhere herein to the contrary notwithstanding, it is understood and acknowledged by the Company that: (i) none of the Participants has been asked by the Company to agree, nor has any Participant agreed, to desist from purchasing or selling, long and/or short, securities of the Company, or “derivative” securities based on securities issued by the Company or to hold the Securities for any specified term; (ii) past or future open market or other transactions by any Participant, specifically including, without limitation, Short Sales or “derivative” transactions, before or after the closing of this or future private placement transactions, may negatively impact the market price of the Company’s publicly-traded securities; (iii) any Participant, and counter-parties in “derivative” transactions to which any such Participant is a party, directly or indirectly, presently may have a “short” position in the Shares, and (iv) each Participant shall not be deemed to have any affiliation with or control over any arm’s length counter-party in any “derivative” transaction. The Company further understands and acknowledges that (y) one or more Participants may engage in hedging activities at various times during the period that the Securities are outstanding, including, without limitation, during the periods that the value of the shares underlying the Warrants deliverable with respect to Securities are being determined, and (z) such hedging activities (if any) could reduce the value of the existing stockholders’ equity interests in the Company at and after the time that the hedging activities are being conducted. The Company acknowledges that such aforementioned hedging activities do not constitute a breach of this Agreement.

 

4.24        Regulation M Compliance. The Company has not, and to its knowledge no one acting on its behalf has, (i) taken, directly or indirectly, any action designed to cause or to result in the stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of any of the Securities, (ii) sold, bid for, purchased, or, paid any compensation for soliciting purchases of, any of the Securities, or (iii) paid or agreed to pay to any person any compensation for soliciting another to purchase any other securities of the Company, other than, in the case of clauses (ii) and (iii), compensation paid to the Placement Agent in connection with the placement of the Securities.

 

4.25        FDA. As to each product subject to the jurisdiction of the U.S. Food and Drug Administration (“FDA”) under the Federal Food, Drug and Cosmetic Act, as amended, and the regulations thereunder (“FDCA”) that is manufactured, packaged, labeled, tested, distributed, sold, and/or marketed by the Company (each such product, a “Pharmaceutical Product”), such Pharmaceutical Product is being manufactured, packaged, labeled, tested, distributed, sold and/or

 

9

 

marketed by the Company in compliance with all applicable requirements under FDCA and similar laws, rules and regulations relating to registration, investigational use, premarket clearance, licensure, or application approval, good manufacturing practices, good laboratory practices, good clinical practices, product listing, quotas, labeling, advertising, record keeping and filing of reports, except where the failure to be in compliance would not reasonably be expected to have a Material Adverse Effect. Except as disclosed in the SEC Reports, there is no pending, completed or, to the Company’s knowledge, threatened, action (including any lawsuit, arbitration, or legal or administrative or regulatory proceeding, charge, complaint, or investigation) against the Company, and the Company has not received any notice, warning letter or other communication from the FDA or any other governmental entity, which (i) contests the premarket clearance, licensure, registration, or approval of, the uses of, the distribution of, the manufacturing or packaging of, the testing of, the sale of, or the labeling and promotion of any Pharmaceutical Product, (ii) withdraws its approval of, requests the recall, suspension, or seizure of, or withdraws or orders the withdrawal of advertising or sales promotional materials relating to, any Pharmaceutical Product, (iii) imposes a clinical hold on any clinical investigation by the Company, (iv) enjoins production at any facility of the Company, (v) enters or proposes to enter into a consent decree of permanent injunction with the Company, or (vi) otherwise alleges any violation of any laws, rules or regulations by the Company, and which, either individually or in the aggregate, would have a Material Adverse Effect. The properties, business and operations of the Company have been and are being conducted in all material respects in accordance with all applicable laws, rules and regulations of the FDA. The Company has not been informed by the FDA that the FDA will prohibit the marketing, sale, license or use in the United States of any product proposed to be developed, produced or marketed by the Company nor, to the knowledge of the company, has the FDA expressed in any meeting or written communication with the Company any concern as to approving or clearing for marketing any product being developed or proposed to be developed by the Company.

 

4.26        Office of foreign assets control. neither nor, to the Company’s knowledge, any director, officer, agent, employee or affiliate of the Company is currently subject to any U.S. sanctions administered by the Office of Foreign Assets Control of the U.S. Treasury Department (“OFAC”).

 

4.27        U.S. Real Property Holding Corporation. The Company is not and has never been a U.S. real property holding corporation within the meaning of Section 897 of the Internal Revenue Code of 1986, as amended, and the Company shall so certify upon Participant’s request.

 

4.28        Money Laundering. The operations of the Company are and have been conducted at all times in compliance with applicable financial record-keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, applicable money laundering statutes and applicable rules and regulations thereunder (collectively, the “Money Laundering Laws”), and no Action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company with respect to the Money Laundering Laws is pending or, to the knowledge of the Company, threatened.

 

4.29        No General Solicitation. Neither the Company nor any person acting on behalf of the Company has offered or sold any of the Securities by any form of general solicitation or general advertising. The Company has offered the Securities only to the Participants and certain other “accredited investors” within the meaning of Rule 501 under the Securities Act.

 

10

 

4.30        No Disqualification Events. With respect to the Securities to be offered and sold hereunder in reliance on Rule 506 under the Securities Act, none of the Company, any of its predecessors, any affiliated issuer, any director, executive officer, other officer of the Company participating in the offering hereunder, or, to the knowledge of the Company, any beneficial owner (as that term is defined in Rule 13d-3 under the Exchange Act) of 20% or more of the Company’s outstanding voting equity securities, calculated on the basis of voting power, nor any promoter (as that term is defined in Rule 405 under the Securities Act) connected with the Company in any capacity at the time of sale (each, an “Issuer Covered Person” and, together, “Issuer Covered Persons”) is subject to any of the “Bad Actor” disqualifications described in Rule 506(d)(1)(i) to (viii) under the Securities Act (a “Disqualification Event”), except for a Disqualification Event covered by Rule 506(d)(2) or (d)(3). The Company has exercised reasonable care to determine whether any Issuer Covered Person is subject to a Disqualification Event. The Company has complied, to the extent applicable, with its disclosure obligations under Rule 506(e), and has furnished to the Participants a copy of any disclosures provided thereunder.

 

4.31        Other Covered Persons. Other than the Placement Agents, the Company is not aware of any person (other than any Issuer Covered Person) that has been or will be paid (directly or indirectly) remuneration for solicitation of Participants in connection with the sale of any Securities.

 

4.32        Notice of Disqualification Events. The Company will notify the Participants and the Placement Agents in writing, prior to the Closing Date of (i) any Disqualification Event relating to any Issuer Covered Person and (ii) any event that would, with the passage of time, reasonably be expected to become a Disqualification Event relating to any Issuer Covered Person, in each case of which it is aware.

 

4.33        Securities Act Exemption. Assuming and relying in part on the truth and accuracy of Participants’ representations and warranties in Section 5 of this Agreement, the offer, sale and issuance of the Securities is exempt from registration under the Securities Act.

 

4.34        Brokers. Except for the engagement of JMP Securities LLC, H. C. Wainwright & Co. and Ladenburg Thalmann Financial Services Inc. (collectively, the “Placement Agents”) by the Company, neither the Company nor any of the officers, directors or employees of the Company has employed any broker or finder in connection with the transaction contemplated by this Agreement. The Company shall indemnify each Participant from and against any broker’s, finder’s or agent’s fees for which the Company is responsible.

 

SECTION 5.        REPRESENTATIONS, WARRANTIES AND COVENANTS OF THE PARTICIPANT.

 

5.1          Authority, Approval and Enforceability.

 

Each Participant, severally and not jointly, represents and warrants to and covenants with the Company that:

 

(a)           Participant has full power and authority to execute, deliver and perform its obligations under this Agreement and all agreements, instruments and documents contemplated hereby, and all action of Participant necessary for such execution, delivery and performance has been duly taken.

 

11

 

(b)           Participant’s execution, delivery and performance of this Agreement has been duly authorized by all requisite action by Participant. Upon the execution and delivery by Participant, and assuming the valid execution and delivery of this Agreement by the Company, this Agreement will constitute a valid and binding obligation of Participant, enforceable in accordance with its terms, except as enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors’ and contracting parties’ rights generally and except as enforceability may be subject to general principles of equity (regardless of whether such enforceability is considered in a proceeding in equity or at law), including specific performance, and except to the extent that the enforceability of the indemnification provisions of Section 9.4 may be legally unenforceable.

 

5.2          Investment Representations. Each Participant understands that the Securities have not been registered under the Securities Act. Each Participant also understands that the Securities are being offered and sold pursuant to an exemption from registration contained in the Securities Act based in part upon Participant’s representations contained in the Agreement. Each Participant hereby represents and warrants as follows:

 

(a)           Participant has substantial experience in evaluating and investing in private placement transactions of securities in companies similar to the Company so that it is capable of evaluating the merits and risks of its investment in the Company and has the capacity to protect its own interests. Participant must bear the economic risk of this investment indefinitely unless the Securities are registered pursuant to the Securities Act, or an exemption from registration is available. Participant understands that there is no assurance that any exemption from registration under the Securities Act will be available and that, even if available, such exemption may not allow Participant to transfer all or any portion of the Securities under the circumstances, in the amounts or at the times Participant might propose.

 

(b)           Participant has been advised or is aware of the provisions of Rule 144 promulgated under the Securities Act, which permits limited resale of shares purchased in a private placement subject to the satisfaction of certain conditions.

 

(c)           The Participant agrees that it will not sell, pledge, assign, transfer, otherwise dispose of or reduce its risk with respect to (collectively, “Transfer”) any of the Securities unless the Transfer will be made pursuant to an exemption from the registration requirements of the Securities Act or pursuant to an effective registration statement under the Securities Act and pursuant to an exemption from any applicable state securities laws or an effective registration or other qualification under any applicable state securities laws. The Participant understands that exemptions from such registration requirements are limited. The Company is under no obligation to register the Securities except as provided in Section 9.

 

(d)           The Participant acknowledges and agrees that the Securities are subject to certain restrictions as to resale under the federal and state securities laws. The Participant agrees and understands that stop transfer instructions will be given to the transfer agent for the Shares and Warrant Shares, and each book entry therefor shall include, or, if applicable, each share certificate and each certificate delivered on transfer of or in substitution for any such certificate, shall have affixed, a legend in substantially the following form:

 

“The shares represented by this book entry or certificate have not been registered under the Securities Act of 1933, as amended (the “Act”), and may not be offered, sold or

 

12

 

otherwise transferred, assigned, pledged or hypothecated unless and until registered under the Act or unless the Company has received an opinion of counsel satisfactory to the Company and its counsel that such registration is not required.”

 

(e)           The book entries or certificates evidencing the Shares and Warrant Shares shall not contain any legend restricting the transfer thereof (including the legend set forth above in Section 5.2(d)): (A) while a registration statement covering the sale or resale of such security is effective under the Securities Act, or (B) following any sale of such Shares and/or Warrant Shares pursuant to Rule 144, or (C) if such Shares and/or Warrant Shares are eligible for sale under Rule 144(b)(1), or (D) if such legend is not required under applicable requirements of the Securities Act (including judicial interpretations and pronouncements issued by the staff of the SEC) (collectively, the “Unrestricted Conditions”). Upon request by the Participant, the Company shall cause its counsel to issue a legal opinion to its transfer agent promptly after such time as the Unrestricted Conditions have been met, if required by the Company’s transfer agent to effect the issuance of the Shares and/or Warrant Shares without a restrictive legend or removal of the legend hereunder; provided that no such opinion will be required if (A) in this Section is the only Unrestricted Condition satisfied. If the Unrestricted Conditions are met at the time of issuance of the Shares and/or Warrant Shares, then such Shares and/or Warrant Shares shall be issued free of all legends. The Company agrees that following the Effective Date (as defined below) at such time as the Unrestricted Conditions are met, it will, no later than three (3) Trading Days (as defined below) following the delivery by the Participant to the Company or the transfer agent of the written notice that the Unrestricted Conditions are met, remove or cause to be removed all restrictive and other legends from the book entries and certificates for the applicable Shares and/or Warrant Shares. For the purposes hereof, “Trading Day” means any day on which the ordinary shares are traded on the Nasdaq Stock Market, or, if the Nasdaq Stock Market is not the principal trading market for the ordinary shares, then on the principal securities exchange or securities market on which the ordinary shares are then traded; provided that “Trading Day” shall not include any day on which the ordinary shares are scheduled to trade on such exchange or market for less than 4.5 hours or any day that the ordinary shares are suspended from trading during the final hour of trading on such exchange or market (or if such exchange or market does not designate in advance the closing time of trading on such exchange or market, then during the hour ending at 4:00 p.m., New York Time)

 

(f)            Participant is acquiring the Securities for Participant’s own account and not with a view towards their distribution in violation of the Securities Act.

 

(g)           Participant represents that by reason of its, or of its management’s, business or financial experience, Participant has the capacity to protect its own interests in connection with the transactions contemplated in this Agreement. Further, Participant is aware of no publication of any advertisement in connection with the transactions contemplated in the Agreement.

 

(h)           Participant represents that it is an accredited investor within the meaning of Regulation D under the Securities Act.

 

(i)            Participant has had an opportunity to discuss the Company’s business, management and financial affairs with directors, officers and management of the Company and has had the opportunity to review the Company’s operations and facilities. Participant has also

 

13

 

had the opportunity to ask questions of and receive answers from, the Company and its management regarding the terms and conditions of this investment.

 

5.3          Brokers. Other than as disclosed to the Company, neither the Participants nor any of their respective officers, directors or employees has employed any broker or finder in connection with the transaction contemplated by this Agreement. Each Participant shall severally, and not jointly, indemnify the Company and the other Participants from and against any broker’s, finder’s or agent’s fees for which such indemnifying Participant is responsible.

 

5.4          Acknowledgments Regarding Placement Agents. Each Participant acknowledges that each Placement Agent has acted solely as placement agent for the Company in connection with the offering of the Securities by the Company, that certain of the information and data provided to such Participant in connection with the transactions contemplated hereby have not been subjected to independent verification by any Placement Agent, and that no Placement Agent makes any representation or warranty with respect to the accuracy or completeness of such information, data or other related disclosure material. Each Participant further acknowledges that in making its decision to enter into this Agreement and purchase Shares and a Warrant it has relied on its own examination of the Company and the terms of, and consequences, of holding the Securities. Each Participant further acknowledges that the provisions of this Section 5.4 are also for the benefit of, and may also be enforced by, each Placement Agent.

 

SECTION 6.        SURVIVAL OF REPRESENTATIONS, WARRANTIES AND AGREEMENTS. Notwithstanding any investigation made by any party to this Agreement, all covenants, agreements, representations and warranties made by the Company and each Participant herein shall survive the execution of this Agreement and the issuance and sale to the Participants of the Securities and shall terminate upon the subsequent transfer of the Shares pursuant to Section 5 or Section 9.

 

SECTION 7.        CONDITIONS TO COMPANY’S OBLIGATIONS AT THE CLOSING. The Company’s obligation to complete the sale and issuance of the Securities at each Closing shall be subject to the following conditions to the extent not waived by the Company:

 

7.1          Representations and Warranties Correct. The representations and warranties made by each Participant in Section 5 hereof shall be true and correct when made, and shall be true and correct on the date of the applicable Closing.

 

7.2          Covenants Performed. All covenants, agreements and conditions contained in this Agreement to be performed by the Participants on or prior to the date of the applicable Closing shall have been performed or complied with in all material respects.

 

7.3          Qualifications. All authorizations, approvals, or permits, if any, of any governmental authority or regulatory body of the United States or of any state that are binding upon any of the Participants and that are required in connection with the lawful sale and issuance of the Securities at such Closing pursuant to this Agreement shall have been duly obtained and shall be effective on and as of the date of such Closing. No stop order or other order enjoining the sale of the Securities shall have been issued and no proceedings for such purpose shall be pending or, to the knowledge of the Company, threatened by the SEC or any commissioner of corporations or similar officer of any state having jurisdiction over this transaction.

 

14

 

7.4          Legal Investment. At the time of such Closing, the sale and issuance of the Securities to be subscribed for and sold at such Closing shall be legally permitted by all laws and regulations to which the Participant and the Company are subject.

 

SECTION 8.        CONDITIONS TO PARTICIPANTS’ OBLIGATIONS AT THE CLOSING. Each Participant’s obligation to purchase the Securities at each Closing thereby shall be subject to the following conditions to the extent not waived by such Participant:

 

8.1          Representations and Warranties Correct. The representations and warranties made by the Company in Section 4 hereof shall be true and correct when made, and shall be true and correct as of the date of the Initial Closing.

 

8.2          Legal Opinion. Participants shall have received from each of Katzenell Dimant Frank, Israeli counsel to the Company, and Cooley LLP, U.S. counsel to the Company, an opinion letter addressed to the Participants, dated as of the date of the Initial Closing, in a form reasonably accetpable to the Participants.

 

8.3          Covenants Performed. All covenants, agreements and conditions contained herein to be performed by the Company on or prior to the date of the Initial Closing shall have been performed or complied with in all material respects.

 

8.4          Qualifications. All authorizations, approvals, or permits, if any, of any governmental authority or regulatory body of the United States or of any state that are binding upon the Company and that are required in connection with the lawful sale and issuance of the Shares at such Closing pursuant to this Agreement shall have been duly obtained and shall be effective on and as of the date of the Initial Closing. No stop order or other order enjoining the sale of the Securities shall have been issued and no proceedings for such purpose shall be pending or, to the knowledge of the Company, threatened by the SEC, or any commissioner of corporations or similar officer of any state having jurisdiction over this transaction.

 

8.5          Legal Investment. At the time of each Closing, the sale and issuance of the Securities shall be legally permitted by all laws and regulations to which the Participant and the Company are subject.

 

8.6          Compliance Certificate. The Company shall have delivered to Participants, a Compliance Certificate, executed by the Chief Executive Officer of the Company, as of the date of each Closing, to the effect that the conditions, specified in Sections 8.1, 8.3 and 8.4 have been satisfied.

 

8.7          Lock-Up Agreements. The Company’s directors and officers shall have executed and delivered customary “lock-up” agreements with lock-up periods of 180 days from the date of each Closing.

 

In the event that any of the conditions set forth above have not been satisfied as of the date of the Initial Closing, each Participant shall have the right, upon the delivery of written notice to the Company, to terminate this Agreement, and upon the delivery of such written notice, such Participant shall have no further obligations under this Agreement whatsoever, including, without limitation, with respect to the purchase of any Shares or Warrants.

 

15

 

SECTION 9.        REGISTRATION OF THE SHARES; COMPLIANCE WITH THE SECURITIES ACT; ADDITIONAL AGREEMENTS.

 

9.1          Definitions. As used in this Section 9 the following terms shall have the following respective meanings:

 

(a)           “Registrable Shares” shall mean (i) the Shares issued and Warrant Shares issued or issuable pursuant to this Agreement and (ii) any other ordinary shares issued or issuable in respect to the Shares and Warrant Shares (because of stock splits, stock dividends, reclassifications, recapitalizations, or similar events);

 

(b)           “Registration Statement” shall mean any registration statement and shall include any preliminary prospectus, final prospectus, exhibit, supplement or amendment included in or relating to the Registration Statement referred to in Section 9.2 and Section 9.4; and

 

(c)           “Untrue Statement” shall include any untrue statement or alleged untrue statement, or any omission or alleged omission to state in the Registration Statement a material fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading.

 

9.2          Registration Procedures and Expenses. The Company is obligated to do the following:

 

The Company shall:

 

(a)           As soon as reasonably practicable and in either event within thirty (30) days immediately following the date of each Closing, such actual date being referred to as a “Registration Date,” prepare and file with the SEC a registration statement on Form S-3 (or, if Form S-3 is not then available, on such form as is then available) in order to register with the SEC under the Securities Act a sale by the Participants on a delayed or continuous basis pursuant to Rule 415 under the Securities Act any or all of the Registrable Shares through the automated quotation system of the Nasdaq Market or the facilities of any national securities exchange on which the Company’s ordinary shares are then traded, or in privately-negotiated transactions (a “Registration Statement”);

 

(b)           subject to receipt of necessary information from the Participants, use its best efforts to cause such Registration Statement to become effective (the “Effective Date”) within 30 days immediately following the date of the applicable Registration Date (a “Required Effectiveness Date”) and take all other reasonable actions necessary under any federal law or regulation to permit all Registrable Shares to be sold or otherwise disposed of;

 

(c)           if at any time, there is not an effective Registration Statement covering all of the Registrable Shares and the Company shall determine to prepare and file with the SEC a registration statement relating to an offering for its own account or the account of others under the Securities Act of any of its equity securities, other than on Form S-4 or Form S-8 (each as promulgated under the Securities Act) or their then equivalents relating to equity securities to be issued solely in connection with any acquisition of any entity or business or equity securities issuable in connection with stock option or other employee benefit plans, send to each Participant not then eligible to sell all of their Registrable Shares under Rule 144 in a three-

 

16

 

month period, written notice of such determination and if, within ten days after receipt of such notice, any such Participant shall so request in writing, shall include in such registration statement all or any part of such Registrable Shares such Participant requests to be registered; provided that: (i) in the event that, in connection with any underwritten public offering, the managing underwriter(s) thereof shall impose a limitation on the number of ordinary shares which may be included in the Registration Statement because, in such underwriter(s)’ judgment, marketing or other factors dictate such limitation is necessary to facilitate public distribution, then the Company shall be obligated to include in such Registration Statement only such limited portion of the Registrable Shares with respect to which such Participant has requested inclusion hereunder as the underwriter shall permit; (ii) if an offering in connection with which a Participant is entitled to registration under this Section 9.2(c) is an underwritten offering, then each Participant whose Registrable Shares are included in such Registration Statement shall, unless otherwise agreed by the Company, offer and sell such Registrable Shares in an underwritten offering using the same underwriter or underwriters and, subject to the provisions of this Agreement, on the same terms and conditions as other ordinary shares included in such underwritten offering and shall enter into an underwriting agreement in a form and substance reasonably satisfactory to the Company and the underwriter or underwriters; and (iii) upon the effectiveness the registration statement for which piggy-back registration has been provided in this Section 9.2(c), any Event Payments payable to a Participant whose Shares are included in such registration statement shall terminate and no longer be payable;

 

(d)           promptly notify each Participant, at any time when a prospectus relating to such Registration Statement is required to be delivered under the Securities Act, of the happening of any event as a result of which the prospectus included in or relating to such Registration Statement contains an untrue statement of a material fact or omits to state any fact necessary to make the statements therein not misleading;

 

(e)           promptly prepare and file with the SEC, and deliver to each Participant, such amendments and supplements to such Registration Statement and the prospectus used in connection therewith as may be necessary to keep such Registration Statement effective until the earlier of (i) the third anniversary of the date of the Initial Closing or (ii) termination of such obligation as provided in Section 9.8 below;

 

(f)            furnish to each Participant such number of copies of prospectuses in conformity with the requirements of the Securities Act, in order to facilitate the public sale or other disposition of all or any of the Registrable Shares by the Participants;

 

(g)           no later than the applicable Registration Date, file such documents as may be required of the Company for normal state securities law clearance for the resale of the Registrable Shares in which states of the United States as may be reasonably requested by each Participant provided, however, that the Company shall not be required in connection with this paragraph (f) to qualify as a foreign corporation or execute a general consent to service of process in any jurisdiction;

 

(h)           no later than the applicable Registration Date, use its best efforts to cause all Registrable Shares to be listed on each securities exchange, if any, on which equity securities by the Company are then listed; and

 

(i)            bear all expenses in connection with the procedures in Section 9.2, other than (i) fees and expenses, if any, of counsel or other advisers to the Participants, and (ii) any

 

17

 

expenses relating to the sale of the Registrable Shares by the Participants, including broker’s commission, discounts or fees and transfer taxes.

 

9.3          Liquidated Damages. Should an Event (as defined below) occur, then upon the occurrence of such Event and on every monthly anniversary thereof until the applicable Event is cured, the Company shall pay to each Participant an amount in cash, as liquidated damages and not as a penalty, equal to one percent (1.0%) of the aggregate purchase price of the Registrable Shares then held by the Participant (which remedy shall be exclusive of any other remedies available under this Agreement or under applicable law); provided, however, that the total amount of payments pursuant to this Section shall not exceed, when aggregated with all such payments paid to all Participants, five percent (5%) of the aggregate purchase price of the Registrable Shares then held by the Participant. The payments to which a Participant shall be entitled pursuant to this Section are referred to herein as “Event Payments.” Any Event Payments payable pursuant to the terms hereof shall apply on a pro rated basis for any portion of a month prior to the cure of an Event. In the event the Company fails to make Event Payments in a timely manner, such Event Payments shall bear interest at the rate of one percent (1.0%) per month (prorated for partial months) until paid in full. All pro rated calculations made pursuant to this paragraph shall be based upon the actual number of days in such pro rated month. The parties agree that the Company will not be liable for liquidated damages under this Section with respect to (1) any period after the termination of the Company’s obligations under Section 9.8 and (2) any Registrable Shares that are not permitted by the SEC to be included in a Registration Statement, based solely on the SEC’s determination that such Registrable Shares are not permitted to be registered in accordance with Rule 415 under the Securities Act in accordance with the SEC’s review and interpretation of its own guidance or restrictions and only to the extent such cut-back is not based on any action taken by the Company to register shares other than the Registrable Securities after the date hereof (and in such case, the Event Payments shall be calculated to only apply to the percentage of Registrable Securities that are permitted by the SEC to be included in such Registration Statement). In the event that the Company registers some but not all of the Registrable Shares, the 1.0% of liquidated damages referred to above for any monthly period shall be reduced to equal the percentage determined by multiplying 1.0% by a fraction, the numerator of which shall be the number of Registrable Shares for which there is not an effective Registration Statement at such time and the denominator of which shall be the number of Registrable Shares at such time. Notwithstanding the foregoing, the applicable Registration Date or Required Effectiveness Date for a Registration Statement shall be extended without Event Payments hereunder in the event that the Company’s failure to file or obtain the effectiveness of such Registration Statement on a timely basis results from (i) the failure of any Participant to timely provide the Company with information reasonably requested by the Company and necessary to complete the Registration Statement in accordance with the requirements of the Securities Act or (ii) events or circumstances that are not in any way attributable to the Company’s actions or inactions, including, but not limited to, the failure of any Participant to promptly notify the Company when it has sold substantially all of its Registrable Shares covered by a Registration Statement or to otherwise comply with the terms of this Agreement, and in any event, no Participant causing the failure described in (i) or (ii), above shall be entitled to Event Payments relating to the failure caused by such Participant.

 

For such purposes, each of the following shall constitute an “Event”:

 

(i) a Registration Statement is not declared effective on or prior to its applicable Required Effectiveness Date; and

 

18

 

(ii) except as provided for in Section 9.5, after the Effective Date of a Registration Statement and through the earlier of (i) the third anniversary of the date of the Initial Closing or (ii) the termination of the Company’s obligations under Section 9.8, a Participant is not permitted to sell Registrable Shares under the Registration Statement (or a subsequent Registration Statement filed in replacement thereof) for any reason (other than the fault of such Participant).

 

9.4          Indemnification

 

(a)           The Company agrees to indemnify and hold harmless each Participant and underwriter (and each person, if any, who controls the Participant within the meaning of Section 15 of the Securities Act) from and against any losses, claims, damages or liabilities to which such Participant (or such underwriter or controlling person) may become subject (under the Securities Act or otherwise) insofar as such losses, claims, damages or liabilities (or actions or proceedings in respect thereof) arise out of, or are based upon, any Untrue Statement contained in the Registration Statement on the Effective Date thereof, or arise out of any failure by the Company to fulfill any undertaking included in the Registration Statement and the Company will reimburse such Participant (or such underwriter or controlling person) for any reasonable legal or other expenses reasonably incurred in investigating, defending or preparing to defend any such action, proceeding or claim; provided, however, that the Company shall not be liable in any such case to the extent that such loss, claim, damage or liability arises out of, or is based upon, an Untrue Statement made in such Registration Statement in reliance upon and in conformity with written information furnished to the Company by or on behalf of such Participant specifically for use in preparation of the Registration Statement, or the failure of such Participant to comply with the covenants and agreements contained in Section 9.5 hereof respecting the sale of the Registrable Shares or any statement or omission in any prospectus that is corrected in any subsequent prospectus that was delivered to the Participant prior to the pertinent sale or sales by the Participant.

 

(b)           Each Participant, severally and not jointly, agrees to indemnify and hold harmless the Company and underwriter (and each person, if any, who controls the Company within the meaning of Section 15 of the Securities Act, each officer of the Company who signs the Registration Statement and each director of the Company) from and against any losses, claims, damages or liabilities to which the Company (or any such underwriter, officer, director or controlling person) may become subject (under the Securities Act or otherwise), insofar as such losses, claims, damages or liabilities (or actions or proceedings in respect thereof) arise out of, or are based upon, any Untrue Statement contained in the Registration Statement on the Effective Date thereof if such Untrue Statement was made in reliance upon and in conformity with written information furnished by or on behalf of such Participant specifically for use in preparation of the Registration Statement, and such Participant will reimburse the Company (or such underwriter, officer, director or controlling person), as the case may be, for any legal or other expenses reasonably incurred in investigating, defending or preparing to defend any such action, proceeding or claim; provided that in no event shall any indemnity by a Participant under this Section 9.4 exceed the net proceeds received by such Participant from the sale of the Registrable Shares covered by such Registration Statement.

 

(c)           Promptly after receipt by any indemnified person of a written notice of a claim or the beginning of any action in respect of which indemnity is to be sought against an indemnifying person pursuant to this Section 9.4, such indemnified person shall notify the indemnifying person in writing of such claim or of the commencement of such action, and,

 

19

 

subject to the provisions hereinafter stated, in case any such action shall be brought against an indemnified person and such indemnifying person shall have been notified thereof, such indemnifying person shall be entitled to participate therein, and, to the extent it shall wish, to assume the defense thereof, with counsel reasonably satisfactory to such indemnified person. After notice from the indemnifying person to such indemnified person of its election to assume the defense thereof, such indemnifying person shall not be liable to such indemnified person for any legal expenses subsequently incurred by such indemnified person in connection with the defense thereof; provided, however, that if there exists or shall exist a conflict of interest that would make it inappropriate, in the opinion of counsel to the indemnified person, for the same counsel to represent both the indemnified person and such indemnifying person or any affiliate or associate thereof, the indemnified person shall be entitled to retain its own counsel at the expense of such indemnifying person; provided, however, that no indemnifying person shall be responsible for the fees and expenses of more than one separate counsel for all indemnified parties; provided, however, that no person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation.

 

(d)           If the indemnification provided for in this Section 9.4 is held by a court of competent jurisdiction to be unavailable to an indemnified party with respect to any loss, liability, claim, damage, or expense referred to therein, then the indemnifying party, in lieu of indemnifying such indemnified party hereunder, shall contribute to the amount paid or payable by such indemnified party as a result of such loss, liability, claim, damage, or expense in such proportion as is appropriate to reflect the relative fault of the indemnifying party on the one hand and of the indemnified party on the other in connection with the statements or omissions that resulted in such loss, liability, claim, damage, or expense as well as any other relevant equitable considerations. The relative fault of the indemnifying party and of the indemnified party shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of material fact or the omission to state a material fact relates to information supplied by the indemnifying party or by the indemnified party and the parties’ relative intent, knowledge, access to information, and opportunity to correct or prevent such statement or omission; provided, that in no event shall any contribution by a Participant hereunder exceed the net proceeds received by such Participant from the sale of the Shares covered by the Registration Statement.

 

(e)           Notwithstanding the foregoing, to the extent that the provisions on indemnification and contribution in the underwriting agreement entered into in connection with an underwritten public offering are in conflict with the foregoing provisions, the provisions in the underwriting agreement shall control.

 

9.5          Transfer of Shares After Registration; Notice. Each Participant hereby covenants with the Company not to make any sale of the Registrable Shares after registration without effectively causing the prospectus delivery requirement under the Securities Act to be satisfied, unless a valid exemption from registration under the Securities Act is available. Each Participant acknowledges that there may be times when the Company must suspend the use of the prospectus forming a part of the Registration Statement until such time as an amendment to the Registration Statement has been filed by the Company and declared effective by the SEC, or until such time as the Company has filed an appropriate report with the SEC pursuant to the Exchange Act. Each Participant hereby covenants that it will not sell any Registrable Shares pursuant to said prospectus during the period commencing at the time at which the Company

 

20

 

gives the Participant written notice of the suspension of the use of said prospectus and ending at the time the Company gives the Participant notice that the Participant may thereafter effect sales pursuant to said prospectus, provided, however, that the Company shall not suspend the use of said prospectus more than two times in any twelve month period and the duration of any one such suspension shall not be more than thirty (30) days. The foregoing provisions of this Section 9.5 shall in no manner diminish or otherwise impair the Company’s obligations under Section 9.2 and Section 9.4 hereof.

 

9.6          Reporting Requirements. The Company agrees to use its best efforts to:

 

(a)           make and keep public information available, as those terms are understood and defined in Rule 144 under the Securities Act;

 

(b)           file with the SEC in a timely manner all reports and other documents required of the Company under the Securities Act and the Securities Exchange Act of 1934; and

 

(c)           so long as any of the Participants own Registrable Shares, to furnish to the Participants forthwith upon request a written statement by the Company as to whether it complies with the reporting requirements of said Rule 144, the Securities Act and Securities Exchange Act of 1934, and whether it qualifies as a registrant whose securities may be resold pursuant to SEC Form S-3.

 

9.7          Company Lock-Ups.

 

(a)           During the periods commencing on the date of each Closing and ending on the date immediately following the 180 day anniversary of the date of each Closing (the “Restricted Period”), neither the Company nor any of its subsidiaries shall directly or indirectly issue, offer, sell, grant any option or right to purchase, or otherwise dispose of (or announce any issuance, offer, sale, grant of any option or right to purchase or other disposition of) any equity security or any equity-linked or related security (including, without limitation, any “equity security” (as that term is defined under Rule 405 promulgated under the Securities Act), any Ordinary Share Equivalents, any debt, any preferred shares or any purchase rights). For purposes hereof, “Ordinary Share Equivalents” means any securities of the Company or its subsidiaries which would entitle the holder thereof to acquire at any time ordinary shares, including, without limitation, any debt, preferred shares, rights, options, warrants or other instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, ordinary shares.

 

(b)           Notwithstanding the foregoing, Sections 9.7(a) shall not apply in respect of an Exempt Issuance. For purposes hereof, “Exempt Issuance” shall mean the issuance of (a) ordinary shares or options to employees, officers or directors of, or consultants to, the Company pursuant to any stock or option plan duly adopted by the Board of Directors for such purpose, including, but not limited to, the Company’s 2013 Stock Incentive Subplan and the Company’s Amended and Restated 2009 Stock Incentive Plan and (b) ordinary shares issued upon the conversion or exercise of Ordinary Share Equivalents issued prior to the Effective Date.

 

(c)           Until the Applicable Date (as defined below) and at any time thereafter while any Registration Statement is not effective or any prospectus contained therein is not available for use, the Company shall not file any registration statement under the Securities Act relating to securities that are not the Registrable Shares. For purposes hereof, “Applicable Date”

 

21

 

means the first date on which the resale by the Participant of all its Registrable Shares is covered by one or more effective Registration Statements (and each prospectus contained therein is available for use on such date).

 

9.8          Termination of Obligations. The obligations of the Company pursuant to Sections 9.2 through 9.7 hereof shall cease and terminate upon the earlier to occur of (i) such time as all of the Registrable Shares have been resold or (ii) as to each Participant, such time as all of the Registrable Shares held by such Participant may be sold during any 90 day period pursuant to Rule 144 without being restricted by the volume limitations of Rule 144(e).

 

9.9          Assignability of Registration Rights. The registration rights set forth in this Section 9 are assignable in connection with the assignment of any Registrable Shares.

 

9.10        Integration. The Company shall not sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security (as defined in Section 2 of the Securities Act) that would be integrated with the offer or sale of the Securities for purposes of the rules and regulations of any trading market such that it would require shareholder approval prior to the closing of such other transaction unless shareholder approval is obtained before the closing of such subsequent transaction.

 

9.11        Shareholder Rights Plan. No claim will be made or enforced by the Company or, with the consent of the Company, any other person, that any Participant is an “Acquiring Person” under any control share acquisition, business combination, poison pill (including any distribution under a rights agreement) or similar anti-takeover plan or arrangement in effect or hereafter adopted by the Company, or that any Participant could be deemed to trigger the provisions of any such plan or arrangement, by virtue of receiving Securities under this Agreement or under any other agreement between the Company and the Participants.

 

9.12        Non-Public Information. The Company covenants and agrees that neither it, nor any other person acting on its behalf will provide any Participant or its agents or counsel with any information that constitutes, or the Company reasonably believes constitutes, material non-public information, unless prior thereto such Participant shall have consented to the receipt of such information and agreed with the Company to keep such information confidential. To the extent that the Company delivers any material, non-public information to a Participant without such Participant’s consent, the Company hereby covenants and agrees that such Participant shall not have any duty of confidentiality to the Company or any of its officers, directors, agents, employees or affiliates, or a duty to the Company or any of its officers, directors, agents, employees or affiliates not to trade on the basis of, such material, non-public information, provided that the Participant shall remain subject to applicable law. To the extent that any notice provided pursuant to this Agreement constitutes, or contains, material, non-public information regarding the Company, the Company shall simultaneously file such notice with the SEC pursuant to a Current Report on Form 8-K. The Company understands and confirms that each Participant shall be relying on the foregoing covenant in effecting transactions in securities of the Company.

 

9.13        Use of Proceeds. The Company shall use the net proceeds from the sale of the Securities hereunder for working capital purposes primarily to fund precommercialization scale up activities and, if approved, initial commercialization activities for the Company’s lead drug candidate, Trevyent for PAH, as well as further development of the Company’s AHPA product candidates and shall not use such proceeds: (a) for the satisfaction of any portion of the

 

22

 

Company’s debt (other than payment of trade payables in the ordinary course of the Company’s business and prior practices or debt disclosed in the SEC Reports), (b) for the redemption of any common stock or common stock equivalents except for any Company right of repurchase that may be applicable to exercised stock options, (c) for the settlement of any outstanding litigation or (d) in violation of FCPA or OFAC regulations.

 

9.14        Reservation of Shares. As of the date hereof, the Company has reserved and the Company shall continue to reserve and keep available at all times, free of preemptive rights, a sufficient number of Shares for the purpose of enabling the Company to issue Shares pursuant to this Agreement and shares underlying the Warrants pursuant to any exercise of the Warrants.

 

9.15        Listing of Shares. The Company hereby agrees to use best efforts to maintain the listing or quotation of the Shares on the trading market on which it is currently listed, and prior to or concurrently with the Closing, the Company shall apply to list or quote all of the Shares and shares underlying the Warrants on such trading market and promptly secure the listing of all of the Shares and shares underlying the Warrants on such trading market. The Company further agrees, if the Company applies to have the Shares traded on any other trading market, it will then include in such application all of the Shares and shares underlying the Warrants, and will take such other action as is necessary to cause all of the Shares and shares underlying the Warrants to be listed or quoted on such other trading market as promptly as possible. The Company will then take all action reasonably necessary to continue the listing and trading of its Shares on a trading market and will comply in all respects with the Company’s reporting, filing and other obligations under the bylaws or rules of the trading market. The Company agrees to use best efforts to maintain the eligibility of the Shares for electronic transfer through the Depository Trust Company or another established clearing corporation, including, without limitation, by timely payment of fees to the Depository Trust Company or such other established clearing corporation in connection with such electronic transfer.

 

9.16        Equal Treatment of Participants. No consideration (including any modification of this Agreement) shall be offered or paid to any person to amend or consent to a waiver or modification of any provision of this Agreement unless the same consideration is also offered to all of the parties to this Agreement. For clarification purposes, this provision constitutes a separate right granted to each Participant by the Company and negotiated separately by each Participant, and is intended for the Company to treat the Participants as a class and shall not in any way be construed as the Participants acting in concert or as a group with respect to the purchase, disposition or voting of Securities or otherwise.

 

9.17        Exercise Procedures. The form of Notice of Exercise included in the Warrants set forth the totality of the procedures required of the Participants in order to exercise the Warrants. No additional legal opinion, other information or instructions shall be required of the Participants to exercise their Warrants. Without limiting the preceding sentences, no ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise form be required in order to exercise the Warrants. The Company shall honor exercises of the Warrants and shall deliver shares underlying the Warrants in accordance with the terms, conditions and time periods set forth therein.

 

9.18        Acknowledgment of Dilution. The Company acknowledges that the issuance of the Securities may result in dilution of the outstanding Shares, which dilution may be substantial under certain market conditions. The Company further acknowledges that its obligations,

 

23

 

including, without limitation, its obligation to issue the Shares and shares underlying the Warrants, are unconditional and absolute and not subject to any right of set off, counterclaim, delay or reduction, regardless of the effect of any such dilution or any claim the Company may have against any Participant and regardless of the dilutive effect that such issuance may have on the ownership of the other stockholders of the Company.

 

9.19        Compliance. The Company covenants and agrees that it shall not (and shall not permit any of its subsidiaries or affiliates or any of its or their respective directors, officers, managers, employees, independent contractors, representatives or agents to) promise, authorize or make any payment to, or otherwise contribute any item of value to, directly or indirectly, to any third party, including any Non-U.S. Official (as such term is defined in FCPA), in each case, in violation of the FCPA, the U.K. Bribery Act, or any other applicable anti-bribery or anti-corruption law. The Company further covenants and agrees that it shall (and shall cause each of its subsidiaries and affiliates to) cease all of its or their respective activities, as well as remediate any actions taken by the Company, its subsidiaries or affiliates, or any of their respective directors, officers, managers, employees, independent contractors, representatives or agents in violation of the FCPA, the U.K. Bribery Act, or any other applicable anti-bribery or anti-corruption law. The Company further covenants and agrees that it shall (and shall cause each of its subsidiaries and affiliates to) implement and maintain systems of internal controls (including, but not limited to, accounting systems, purchasing systems and billing systems) to ensure compliance with the FCPA, the U.K. Bribery Act, or any other applicable anti-bribery or anti-corruption law. The Company shall, and shall cause any direct or indirect subsidiary or entity controlled by it, whether now in existence or formed in the future, to comply with the FCPA. The Company shall use its best efforts to cause any direct or indirect subsidiary, whether now in existence or formed in the future, to comply in all material respects with all applicable laws.

 

9.20        Passive Foreign Investment Company. Upon request by the Participant, which shall be limited to one request per each calendar year, the Company shall make due inquiry regarding the Company’s status as a passive foreign investment company under Section 1297 of the Code and shall promptly notify the Participant of such status. If the Company is, in its reasonable opinion, a PFIC, unless otherwise required by law, the Company shall reasonably cooperate with the Participant and use commercially reasonable efforts to provide the Participant with the information required by the Participant for purposes of making a mark-to-market election under Section 1296 of the Code or a qualified electing fund election pursuant to Section 1295 of the Code.

 

SECTION 10.      NOTICES. All notices, requests, consents and other communications hereunder shall be in writing, shall be sent by confirmed facsimile or mailed by first-class registered or certified airmail, or nationally recognized overnight express courier, postage prepaid, and shall be deemed given when so sent and addressed as follows:

 

(a)           if to the Company, to:

 

SteadyMed Ltd.

2603 Camino Ramon, Suite 350

San Ramon, CA 94583

Tel: (925) 272-4999

Attention: Chief Financial Officer

 

24

 

with a copy to:

 

Cooley LLP

3175 Hanover Street

Palo Alto, California 94304

Attention: Michael E. Tenta

 

or to such other person at such other place as the Company shall designate to the Participants in writing; and

 

(b)           if to a Participant, at the address as set forth on such Participant’s signature page at the end of this Agreement, or at such other address or addresses as may have been furnished to the Company in writing.

 

SECTION 11.      MISCELLANEOUS.

 

11.1        Waivers and Amendments. Neither this Agreement nor any provision hereof may be changed, waived, discharged, terminated, modified or amended except upon the written consent of the Company and holders of at least 662/3% of the Shares issued pursuant to this Agreement.

 

11.2        Headings. The headings of the various sections of this Agreement have been inserted for convenience of reference only and shall not be deemed to be part of this Agreement.

 

11.3        Severability. In case any provision contained in this Agreement should be invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions contained herein shall not in any way be affected or impaired thereby.

 

11.4        Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of New York, without regard to conflicts of law principles.

 

11.5        Counterparts. This Agreement may be executed in two or more counterparts, each of which shall constitute an original, but all of which, when taken together, shall constitute but one instrument, and shall become effective when one or more counterparts have been signed by each party hereto and delivered to the other parties.

 

11.6        Successors and Assigns. Except as otherwise expressly provided herein, the provisions hereof shall inure to the benefit of, and be binding upon, the successors, assigns, heirs, executors and administrators of the parties hereto.

 

11.7        Expenses. Each party shall pay all costs and expenses that it incurs with respect to the negotiation, execution, delivery and performance of this Agreement; provided, however, that the Company shall, at each Closing, reimburse the reasonable fees of and expenses, including legal fees, of OrbiMed Advisors LLC incurred in connection with the Offering, not to exceed $100,000 in the aggregate for all Closings.

 

11.8        Entire Agreement. This Agreement and other documents delivered pursuant hereto, including the exhibits, constitute the full and entire understanding and agreement between the parties with regard to the subjects hereof and thereof.

 

25

 

11.9        Publicity. No party shall issue any press releases or otherwise make any public statement with respect to the transactions contemplated by this Agreement without the prior written consent of the other parties, except as may be required by applicable law or regulations, in which case such party shall provide the other parties with reasonable notice of such publicity and/or opportunity to review such disclosure.

 

11.10      Waiver of Conflicts. Each party to this Agreement acknowledges that U.S. counsel for the Company, Cooley LLP (“Cooley”), has in the past and may continue in the future to perform legal services for one or more of the Participants or their affiliates in matters unrelated to the transactions contemplated by this Agreement, including, but not limited to, the representation of the Participants in matters of a similar nature to the transactions contemplated herein. Each party to this Agreement hereby (a) acknowledges that they have had an opportunity to ask for and have obtained information relevant to such representation, including disclosure of the reasonably foreseeable adverse consequences of such representation; (b) acknowledges that with respect to the transactions contemplated herein, Cooley has represented the Company and not any individual Participant or any individual shareholder, director or employee of the Company; and (c) gives its informed consent to Cooley’s representation of the Company in the transactions contemplated by this Agreement and Cooley’s representation of one or more of the Participants or their affiliates in matters unrelated to such transactions.

 

[THE REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK]

 

26

 

Subject to acceptance by the Company, the undersigned has completed this Agreement to evidence his/her subscription for participation in the Offering of Shares and Warrants of the Company, this 29th day of July, 2016 at 10:38 am.

 

PARTICIPANT

 

	
Name   of Participant:
    	
OrbiMed   Israel Partners II, L.P.
    
	
 
    	
 
    
	
/s/ Jonathan Silverstein
    
	
(Signature)
    
	
 
    	
 
    
	
By:
    	
Jonathan   Silverstien
    
	
 
    	
 
    
	
Its:
    	
Director   of the General Partner of the General Partner
    
			

 

Address for Notice and Delivery:

 

Tax ID No.:

 

Telephone:

 

Fax/email:

 

Attention:

 

Total Subscription Amount for both Initial Closing and assumed Second Closing: $7,499,998.85

 

Number of Shares Subscribed for in the Initial Closing: 1,536,098

 

Number of Warrant Shares issuable upon exercise of Warrant Subscribed for in the Initial Closing: 1,536,098

 

Aggregate Purchase Price in the Initial Closing (No. of shares subscribed for in the Initial Closing multiplied by per share purchase price plus no. of warrant shares underlying warrant subscribed for in the Initial Closing multiplied by $0.125): $4,999,998.99

 

The number of Shares to be subscribed for and the aggregate purchase price to be paid in the Second Closing shall be determined pursuant to Section 2 of the Agreement.

 

The Company has accepted this subscription this 29th day of July 2016.

 

	
 
    	
“COMPANY”
    
	
 
    	
 
    
	
 
    	
STEADYMED   LTD.,
    
	
 
    	
an   Israeli incorporated company
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
By:
    	
/s/   Jonathan Rigby
    
	
 
    	
 
    	
Jonathan Rigby, President & CEO
    
	
 
    	
 
    	
 
    
	
 
    	
Address:   2603 Camino Ramon, Suite 350
    
	
 
    	
 San Ramon, CA 94583
    

 

 

Subject to acceptance by the Company, the undersigned has completed this Agreement to evidence his/her subscription for participation in the Offering of Shares and Warrants of the Company, this 29th day of July, 2016 at 10:38 a.m.

 

PARTICIPANT

 

	
Name   of Participant:
    	
OrbiMed   Private Investments VI, L.P.
    
	
 
    	
 
    
	
/s/ Jonathan Silverstein
    
	
(Signature)
    
	
 
    	
 
    
	
By   Jonathan Silverstein
    	
 
    
	
 
    	
 
    
	
Its:Member   of the Managing Member of the General Partner
    	
 
    
				

 

Address for Notice and Delivery:

 

Tax ID No.:

 

Telephone:

 

Fax/email:

 

Attention:

 

Total Subscription Amount for both Initial Closing and assumed Second Closing: $7,499,998.85

 

Number of Shares Subscribed for in the Initial Closing: 1,536,098

 

Number of Warrant Shares issuable upon exercise of Warrant Subscribed for in the Initial Closing: 1,536,098

 

Aggregate Purchase Price in the Initial Closing (No. of shares subscribed for in the Initial Closing multiplied by per share purchase price plus no. of warrant shares underlying warrant subscribed for in the Initial Closing multiplied by $0.125): $4,999,998.99

 

The number of Shares to be subscribed for and the aggregate purchase price to be paid in the Second Closing shall be determined pursuant to Section 2 of the Agreement.

 

The Company has accepted this subscription this 29th day of July 2016.

 

	
 
    	
“COMPANY”
    
	
 
    	
 
    
	
 
    	
STEADYMED   LTD.,
    
	
 
    	
an   Israeli incorporated company
    
	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
By:
    	
/s/   Jonathan Rigby
    
	
 
    	
 
    	
Jonathan Rigby, President & CEO
    
	
 
    	
 
    	
 
    
	
 
    	
Address:   2603 Camino Ramon, Suite 350
    
	
 
    	
 San Ramon, CA 94583
    

 

 

Subject to acceptance by the Company, the undersigned has completed this Agreement to evidence his/her subscription for participation in the Offering of Shares and Warrants of the Company, this 29th day of July, 2016.

 

PARTICIPANT

 

	
Name   of Participant:
    	
Deerfield   Special Situations Fund, L.P.
    
	
 
    	
 
    
	
/s/ David J. Clark
    
	
(Signature)
    
	
 
    
	
By:
    	
David   J. Clark
    
	
Its:
    	
Authorized   Signatory
    
				

 

	
Address for Notice and Delivery:
    
	
 
    
	
Tax ID No.:
    
	
 
    
	
Telephone:
    
	
 
    
	
Fax/email:
    
	
 
    
	
Attention: 
    

 

Total Subscription Amount for both Initial Closing and assumed Second Closing: $999,998.80

 

Number of Shares Subscribed for in the Initial Closing: 204,813

 

Number of Warrant Shares issuable upon exercise of Warrant Subscribed for in the Initial Closing: 204,813

 

Aggregate Purchase Price in the Initial Closing (No. of shares subscribed for in the Initial Closing multiplied by per share purchase price plus no. of warrant shares underlying warrant subscribed for in the Initial Closing multiplied by $0.125): $666,666.32

 

The number of Shares to be subscribed for and the aggregate purchase price to be paid in the Second Closing shall be determined pursuant to Section 2 of the Agreement.

 

The Company has accepted this subscription this 29th day of July 2016.

 

	
 
    	
“COMPANY”
    
	
 
    	
STEADYMED   LTD.,
    
	
 
    	
 
    
	
 
    	
an   Israeli incorporated company
    
	
 
    	
 
    
	
 
    	
By:   
    	
/s/   Jonathan Rigby
    
	
 
    	
 
    	
Jonathan Rigby,   President & CEO
    
	
 
    	
 
    
	
 
    	
Address:   2603 Camino Ramon, Suite 350
    
	
 
    	
San   Ramon, CA 94583
    

 

 

Subject to acceptance by the Company, the undersigned has completed this Agreement to evidence his/her subscription for participation in the Offering of Shares and Warrants of the Company, this 29th day of July, 2016 .

 

PARTICIPANT

 

	
Name of Participant:
    	
Deerfield Private Design Fund   III, L.P.
    
	
 
    
	
/s/ David J. Clark
    
	
(Signature)
    
	
 
    
	
By:
    	
David J. Clark
    
	
Its:
    	
Authorized Signatory
    
			

 

	
Address for Notice and Delivery:
    
	
 
    
	
Tax ID No.:
    
	
 
    
	
Telephone:
    
	
 
    
	
Fax/email:
    
	
 
    
	
Attention: 
    

 

Total Subscription Amount for both Initial Closing and assumed Second Closing: $999,998.79

 

Number of Shares Subscribed for in the Initial Closing:  204,813

 

Number of Warrant Shares issuable upon exercise of Warrant Subscribed for in the Initial Closing:   204,813

 

Aggregate Purchase Price in the Initial Closing (No. of shares subscribed for in the Initial Closing multiplied by per share purchase price plus no. of warrant shares underlying warrant subscribed for in the Initial Closing multiplied by $0.125): $666,666.31

 

The number of Shares to be subscribed for and the aggregate purchase price to be paid in the Second Closing shall be determined pursuant to Section 2 of the Agreement.

 

The Company has accepted this subscription this 29th day of July 2016.

 

	
 
    	
“COMPANY”
    
	
 
    	
 
    
	
 
    	
STEADYMED   LTD.,
    
	
 
    	
an   Israeli incorporated company
    
	
 
    	
 
    
	
 
    	
By:
    	
/s/   Jonathan Rigby
    
	
 
    	
 
    	
Jonathan Rigby,   President & CEO
    
	
 
    	
 
    
	
 
    	
Address:   2603 Camino Ramon, Suite 350
    
	
 
    	
San   Ramon, CA 94583
    

 

 

Subject to acceptance by the Company, the undersigned has completed this Agreement to evidence his/her subscription for participation in the Offering of Shares and Warrants of the Company, this 29th day of July, 2016                          .

 

PARTICIPANT

 

	
Name   of Participant:  Dennis   L. Berman
    	
 
    
	
 
    	
 
    
	
/s/   Dennis L. Berman
    	
 
    
	
(Signature)
    
	
 
    	
 
    
	
By:
    	
Dennis L. Berman
    
	
 
    	
 
    
	
Its:Self
    	
 
    
				

 

Address for Notice and Delivery:

 

Tax ID No.:                                   

 

Telephone:

 

Fax/email:

 

Attention:

 

Total Subscription Amount for both Initial Closing and assumed Second Closing: $199,997.18

 

Number of Shares Subscribed for in the Initial Closing: 40,962

 

Number of Warrant Shares issuable upon exercise of Warrant Subscribed for in the Initial Closing: 40,962

 

Aggregate Purchase Price in the Initial Closing (No. of shares subscribed for in the Initial Closing multiplied by per share purchase price plus no. of warrant shares underlying warrant subscribed for in the Initial Closing multiplied by $0.125): $133,331,31

 

The number of Shares to be subscribed for and the aggregate purchase price to be paid in the Second Closing shall be determined pursuant to Section 2 of the Agreement.

 

The Company has accepted this subscription this 29th day of July 2016.

 

	
 
    	
“COMPANY”
    
	
 
    	
 
    
	
 
    	
STEADYMED   LTD.,
    
	
 
    	
an   Israeli incorporated company
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
By:
    	
/s/   Jonathan Rigby
    
	
 
    	
 
    	
Jonathan   Rigby, President & CEO
    
	
 
    	
 
    
	
 
    	
Address:   2603 Camino Ramon, Suite 350
    
	
 
    	
San   Ramon, CA 94583
    

 

 

Subject to acceptance by the Company, the undersigned has completed this Agreement to evidence his/her subscription for participation in the Offering of Shares and Warrants of the Company, this 29th day of July, 2016.

 

PARTICIPANT

 

Name of Participant: Federated Kaufmann Fund, a protfolio of Federated Equity Funds

 

	
/s/   Hans P. Utsch
    	
 
    
	
(Signature)
    

 

By:Hans P. Utsch

 

Its:Vice President, Federated Global Investment Management, as attorney-in-fact for Federated Kaufmann Fund, a portfolio of Federated Equity Funds

Address for Notice and Delivery

 

Tax ID No.:

 

Telephone:

 

Fax/email:

 

Attention:

 

Total Subscription Amount for both Initial Closing and assumed Second Closing: $5,731,234.39

 

Number of Shares Subscribed for in the Initial Closing: 1,173,832

 

Number of Warrant Shares issuable upon exercise of Warrant Subscribed for in the Initial Closing:1,173,832

 

Aggregate Purchase Price in the Initial Closing (No. of shares subscribed for in the Initial Closing multiplied by per share purchase price plus no. of warrant shares underlying warrant subscribed for in the Initial Closing multiplied by $0.125): $3,820,823.16

 

The number of Shares to be subscribed for and the aggregate purchase price to be paid in the Second Closing shall be determined pursuant to Section 2 of the Agreement.

 

The Company has accepted this subscription this 29th day of July 2016.

 

	
 
    	
“COMPANY”
    
	
 
    	
 
    
	
 
    	
STEADYMED   LTD.,
    
	
 
    	
an   Israeli incorporated company
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
By:
    	
/s/   Jonathan Rigby
    
	
 
    	
 
    	
Jonathan   Rigby, President & CEO
    
	
 
    	
 
    
	
 
    	
Address:   2603 Camino Ramon, Suite 350
    
	
 
    	
San   Ramon, CA 94583
    

 

 

Subject to acceptance by the Company, the undersigned has completed this Agreement to evidence his/her subscription for participation in the Offering of Shares and Warrants of the Company, this 29th day of July, 2016.

 

PARTICIPANT

 

Name of Participant:Federated Kaufmann Small Cap Fund, a portfolio of Federated Equity Funds

 

	
/s/   Hans P. Utsch
    	
 
    	
 
    
	
(Signature)
    	
 
    	
 
    
	
By:Hans   P. Utsch
    	
 
    	
 
    

 

 

Its:Vice President, Federated Global Investment Management, as attorney-in-fact for Federated Kaufmann Small Cap Fund, a portfolio of Federated Equity Funds

 

Address for Notice and Delivery:

 

Tax ID No.:                            

 

Telephone:                            

 

Fax/email:                            

 

Attention:                            

 

Total Subscription Amount for both Initial Closing and assumed Second Closing: $729,445.45

 

Number of Shares Subscribed for in the Initial Closing: 149,400

 

Number of Warrant Shares issuable upon exercise of Warrant Subscribed for in the Initial Closing: 149,400

 

Aggregate Purchase Price in the Initial Closing (No. of shares subscribed for in the Initial Closing multiplied by per share purchase price plus no. of warrant shares underlying warrant subscribed for in the Initial Closing multiplied by $0.125): $486,297

 

The number of Shares to be subscribed for and the aggregate purchase price to be paid in the Second Closing shall be determined pursuant to Section 2 of the Agreement.

 

The Company has accepted this subscription this 29th day of July 2016.

 

	
 
    	
“COMPANY”
    
	
 
    	
 
    	
 
    
	
 
    	
STEADYMED   LTD.,
    
	
 
    	
an   Israeli incorporated company
    
	
 
    	
 
    	
 
    
	
 
    	
By:
    	
/s/   Jonathan Rigby
    
	
 
    	
 
    	
Jonathan Rigby, President & CEO
    
	
 
    	
 
    	
 
    
	
 
    	
Address:   2603 Camino Ramon, Suite 350
    
	
 
    	
San   Ramon, CA 94583
    

 

 

Subject to acceptance by the Company, the undersigned has completed this Agreement to evidence his/her subscription for participation in the Offering of Shares and Warrants of the Company, this 29th day of July, 2016.

 

PARTICIPANT

 

Name of Participant:  Federated Kaufmann Fund II, a portfolio of Federated Insurance Series

 

	
/s/   Hans P. Utsch
    	
 
    	
 
    
	
(Signature)
    	
 
    	
 
    
	
By:Hans   P. Utsch
    	
 
    	
 
    

 

 

Its:Vice President, Federated Global Investment Management, as attorney-in-fact for Federated Kaufmann Funds II, a portfolio of Federated Insurance Series

 

Address for Notice and Delivery:

 

Tax ID No.:                            

 

Telephone:                            

 

Fax/email:                            

 

Attention:                            

 

Total Subscription Amount for both Initial Closing and assumed Second Closing: $139,317.24

 

Number of Shares Subscribed for in the Initial Closing: 28,534

 

Number of Warrant Shares issuable upon exercise of Warrant Subscribed for in the Initial Closing: 28,534

 

Aggregate Purchase Price in the Initial Closing (No. of shares subscribed for in the Initial Closing multiplied by per share purchase price plus no. of warrant shares underlying warrant subscribed for in the Initial Closing multiplied by $0.125): $92,878.17

 

The number of Shares to be subscribed for and the aggregate purchase price to be paid in the Second Closing shall be determined pursuant to Section 2 of the Agreement.

 

The Company has accepted this subscription this 29th day of July 2016.

 

	
 
    	
“COMPANY”
    
	
 
    	
 
    	
 
    
	
 
    	
STEADYMED   LTD.,
    
	
 
    	
an   Israeli incorporated company
    
	
 
    	
 
    	
 
    
	
 
    	
By:
    	
/s/   Jonathan Rigby
    
	
 
    	
 
    	
Jonathan Rigby, President & CEO
    
	
 
    	
 
    	
 
    
	
 
    	
Address:   2603 Camino Ramon, Suite 350
    
	
 
    	
San   Ramon, CA 94583
    

 

 

Subject to acceptance by the Company, the undersigned has completed this Agreement to evidence his/her subscription for participation in the Offering of Shares and Warrants of the Company, this 29th day of July, 2016.

 

PARTICIPANT

 

Name of Participant: Shrewsbury Capital Partners LLC

 

	
/s/   Jonathan Gold
    	
 
    
	
(Signature)
    	
 
    

 

By:Jonathan Gold

 

Its:Managing Member

 

Address for Notice and Delivery:

 

Tax ID No.:

 

Telephone:

 

Fax/email:

 

Attention:

 

Total Subscription Amount for both Initial Closing and assumed Second Closing: $249,998.84

 

Number of Shares Subscribed for in the Initial Closing: 51,203

 

Number of Warrant Shares issuable upon exercise of Warrant Subscribed for in the Initial Closing: 51,203

 

Aggregate Purchase Price in the Initial Closing (No. of shares subscribed for in the Initial Closing multiplied by per share purchase price plus no. of warrant shares underlying warrant subscribed for in the Initial Closing multiplied by $0.125): $166,665.77

 

The number of Shares to be subscribed for and the aggregate purchase price to be paid in the Second Closing shall be determined pursuant to Section 2 of the Agreement.

 

The Company has accepted this subscription this 29th day of July 2016.

 

	
 
    	
“COMPANY”
    
	
 
    	
 
    
	
 
    	
STEADYMED   LTD.,
    
	
 
    	
an   Israeli incorporated company
    
	
 
    	
 
    
	
 
    	
By:
    	
/s/   Jonathan Rigby
    
	
 
    	
Jonathan Rigby, President & CEO
    
	
 
    	
 
    
	
 
    	
Address:   2603 Camino Ramon, Suite 350
    
	
 
    	
 San Ramon, CA 94583
    

 

 

Subject to acceptance by the Company, the undersigned has completed this Agreement to evidence his/her subscription for participation in the Offering of Shares and Warrants of the Company, this 29th day of July, 2016.

 

PARTICIPANT

 

Name of Participant:SteadyMed Investors III LLC

 

	
/s/ Keith Bank
    	
 
    
	
(Signature)
    	
 
    

 

By:Keith Bank

 

Its:VManager

 

Address for Notice and Delivery:

 

Tax ID No.:

 

Telephone:

 

Fax/email:

 

Attention:

 

Total Subscription Amount for both Initial Closing and assumed Second Closing: $1,299,999.39

 

Number of Shares Subscribed for in the Initial Closing: 266,257

 

Number of Warrant Shares issuable upon exercise of Warrant Subscribed for in the Initial Closing: 266,257

 

Aggregate Purchase Price in the Initial Closing (No. of shares subscribed for in the Initial Closing multiplied by per share purchase price plus no. of warrant shares underlying warrant subscribed for in the Initial Closing multiplied by $0.125): $866,666.54

 

The number of Shares to be subscribed for and the aggregate purchase price to be paid in the Second Closing shall be determined pursuant to Section 2 of the Agreement.

 

The Company has accepted this subscription this 29th day of July 2016.

 

	
 
    	
“COMPANY”
    
	
 
    	
 
    
	
 
    	
STEADYMED   LTD.,
    
	
 
    	
an   Israeli incorporated company
    
	
 
    	
 
    
	
 
    	
By:
    	
/s/   Jonathan Rigby
    
	
 
    	
Jonathan Rigby, President & CEO
    

 

 

Subject to acceptance by the Company, the undersigned has completed this Agreement to evidence his/her subscription for participation in the Offering of Shares and Warrants of the Company, this 29th day of July, 2016.

 

PARTICIPANT

 

Name of Participant:Robert J. Barnard

 

	
/s/   Robert J. Barnard
    	
 
    
	
(Signature)
    	
 
    
	
 
    	
 
    
	
By:Robert   J. Barnard
    	
 
    

 

Its:Vice President, Federated Global Investment Management, as attorney-in-fact for Federated Kaufmann Funds II, a portfolio of Federated Insurance Series

 

Address for Notice and Delivery:

 

Tax ID No.:

 

Telephone:

 

Fax/email:

 

Attention:

 

Total Subscription Amount for both Initial Closing and assumed Second Closing: 249,998.89

 

Number of Shares Subscribed for in the Initial Closing: 51,203

 

Number of Warrant Shares issuable upon exercise of Warrant Subscribed for in the Initial Closing: 51,203

 

Aggregate Purchase Price in the Initial Closing (No. of shares subscribed for in the Initial Closing multiplied by per share purchase price plus no. of warrant shares underlying warrant subscribed for in the Initial Closing multiplied by $0.125): $166,665.77

 

The number of Shares to be subscribed for and the aggregate purchase price to be paid in the Second Closing shall be determined pursuant to Section 2 of the Agreement.

 

The Company has accepted this subscription this 29th day of July 2016.

 

	
 
    	
“COMPANY”
    
	
 
    	
 
    
	
 
    	
STEADYMED   LTD.,
    
	
 
    	
an   Israeli incorporated company
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
By:   /s/ Jonathan Rigby
    
	
 
    	
Jonathan   Rigby, President & CEO
    

 

 

Subject to acceptance by the Company, the undersigned has completed this Agreement to evidence his/her subscription for participation in the Offering of Shares and Warrants of the Company, this 29th day of July, 2016.

 

PARTICIPANT

 

Name of Participant:Brown Bear Holdings LP

 

	
/s/   Brian J. Stark
    	
 
    
	
(Signature)
    	
 
    
	
 
    	
 
    
	
By:Hbrian   J. Stark
    	
 
    
	
 
    	
 
    
	
Its:Manager   of its Manager
    	
 
    

 

Address for Notice and Delivery:

 

Tax ID No.:

 

Telephone:

 

Fax/email:

 

Attention:

 

Total Subscription Amount for both Initial Closing and assumed Second Closing: $1,813,238.02

 

Number of Shares Subscribed for in the Initial Closing: 371,375

 

Number of Warrant Shares issuable upon exercise of Warrant Subscribed for in the Initial Closing 371,375

 

Aggregate Purchase Price in the Initial Closing (No. of shares subscribed for in the Initial Closing multiplied by per share purchase price plus no. of warrant shares underlying warrant subscribed for in the Initial Closing multiplied by $0.125): $1,208,825.63

 

The number of Shares to be subscribed for and the aggregate purchase price to be paid in the Second Closing shall be determined pursuant to Section 2 of the Agreement.

 

The Company has accepted this subscription this 29th day of July 2016.

 

	
 
    	
“COMPANY”
    
	
 
    	
 
    
	
 
    	
STEADYMED   LTD.,
    
	
 
    	
an   Israeli incorporated company
    
	
 
    	
 
    
	
 
    	
By:   /s/ Jonathan Rigby
    
	
 
    	
Jonathan   Rigby, President & CEO
    
	
 
    	
 
    
	
 
    	
Address:   2603 Camino Ramon, Suite 350
    
	
 
    	
San   Ramon, CA 94583
    

 

 

Subject to acceptance by the Company, the undersigned has completed this Agreement to evidence his/her subscription for participation in the Offering of Shares and Warrants of the Company, this 29th day of July, 2016.

 

PARTICIPANT

 

Name of Participant:Brian J. Stark

 

	
/s/ Brian J. Stark
    	
 
    
	
(Signature)
    

 

By:Hans P. Utsch

 

Its:Self

 

Address for Notice and Delivery:

 

 

Tax ID No.:

 

Telephone:

 

Fax/email:

 

Attention:

 

Total Subscription Amount for both Initial Closing and assumed Second Closing: $4,586,758.63

 

Number of Shares Subscribed for in the Initial Closing: 939,428

 

Number of Warrant Shares issuable upon exercise of Warrant Subscribed for in the Initial Closing: 939,428

 

Aggregate Purchase Price in the Initial Closing (No. of shares subscribed for in the Initial Closing multiplied by per share purchase price plus no. of warrant shares underlying warrant subscribed for in the Initial Closing multiplied by $0.125): $3,057,838.14.

 

The number of Shares to be subscribed for and the aggregate purchase price to be paid in the Second Closing shall be determined pursuant to Section 2 of the Agreement.

 

The Company has accepted this subscription this 29th day of July 2016.

 

	
 
    	
“COMPANY”
    
	
 
    	
 
    
	
 
    	
STEADYMED   LTD.,
    
	
 
    	
an   Israeli incorporated company
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
By:   
    	
/s/   Jonathan Rigby
    
	
 
    	
 
    	
Jonathan Rigby, President & CEO
    
	
 
    	
 
    
	
 
    	
Address:   2603 Camino Ramon, Suite 350
    
	
 
    	
 San Ramon, CA 94583
    

 

 

EXHIBIT A

 

FORM OF WARRANT

 

 

THIS WARRANT AND THE SECURITIES PURCHASABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FILED UNDER SAID ACT AND ANY APPLICABLE STATE SECURITIES LAWS, UNLESS AN EXEMPTION FROM SUCH REGISTRATION IS AVAILABLE.

 

STEADYMED LTD.

 

WARRANT

 

dated as of August [·], 2016

 

THIS CERTIFIES THAT, for value received, [·] or its successors or permitted assigns (such Person and such successors and assigns each being the “Warrant Holder” with respect to the Warrant held by it), at any time and from time to time on any Business Day on or prior to 5:00 p.m. (New York City time), on the Expiration Date (as herein defined), is entitled (a) to subscribe for the purchase from SteadyMed Ltd., an Israeli incorporated company (the “Company”), [·] Shares at a price per Share equal to the Exercise Price (as herein defined), and (b) to the other rights set forth herein; provided that the number of Shares issuable upon any exercise of this Warrant and the Exercise Price shall be adjusted and readjusted from time to time in accordance with Section 5; and provided further that the number of Shares issuable upon any exercise of this Warrant are subject to certain limitations in accordance with Section 2(a). By accepting delivery hereof, the Warrant Holder agrees to be bound by the provisions hereof.

 

IN FURTHERANCE THEREOF, the Company irrevocably undertakes and agrees for the benefit of the Warrant Holder as follows:

 

Section 1.                                           Definitions and Construction.

 

(a)                                 Certain Definitions. As used herein (the following definitions being applicable in both singular and plural forms):

 

“Affiliate” means, with respect to any Person, any other Person that directly or indirectly controls, is controlled by, or is under common control with such Person.

 

“Appraised Value” means at any time the fair market value thereof determined in good faith by the Board of Directors of the Company as of a date which is within ten (10) days of the date as of which the determination is to be made, subject to the rights of the Requisite Holders pursuant to Section 5(n).

 

“Business Day” means any day except a Saturday, Sunday or other day on which commercial banks in New York City are authorized by law to close.

 

“Closing Price” means, for any trading day with respect to a Share, (a) the last reported sale price on such day on the principal national securities exchange on which the Shares are listed or admitted to trading or, if no such reported sale takes place on any such day, the average of the closing bid and asked prices thereon, as reported in The Wall Street Journal, or (b) if such Shares shall not be listed or admitted to trading on a national securities exchange, the last reported sales price on the NASDAQ National Market System or, if no such reported sale takes place on any such day, the average of the closing bid and asked prices thereon, as reported in The Wall Street Journal, or (c) if such Shares shall not be quoted on such National Market System nor listed or admitted to trading on a national securities exchange, then the average of the closing bid and asked prices, as reported by The Wall Street Journal for the

 

1

 

over-the-counter market; provided that if clause (a), (b), or (c) applies and no price is reported in The Wall Street Journal for any trading day, then the price reported in The Wall Street Journal for the most recent prior trading day shall be deemed to be the price reported for such trading day. The Closing Price with respect to a Share shall be adjusted for any stock dividend, stock split, stock combination or other similar transaction during the applicable calculation period.

 

“Commission” means the Securities and Exchange Commission or any other Federal agency administering the Securities Act at the time.

 

“Exchange Act” means the Securities Exchange Act of 1934, or any successor Federal statute, and the rules and regulations of the Commission thereunder, all as the same shall be in effect at the time.

 

“Exercise Amount” means for any number of Warrant Shares as to which this Warrant is being exercised the product of (i) such number of Warrant Shares times (ii) the Exercise Price.

 

“Exercise Price” means $3.5995 per Warrant Share, as adjusted from time to time pursuant to Section 5.

 

“Expiration Date” means August 2, 2021.

 

“Initial Holder” means [·].

 

“Market Price” on any day means (a) the unweighted average of the daily Closing Prices per Share for the twenty (20) consecutive trading days prior to such date or (b) if clauses (a), (b) and (c) of the definition of “Closing Price” are inapplicable, then the Appraised Value as of such day shall apply; provided that for purposes of the application of Section 5(b) to a Share Distribution pursuant to a public offering registered under the Securities Act, “Market Price” means the Closing Price per Share for the trading day preceding the effective date of the registration statement with respect to such public offering (or in the case of an initial public offering, the price per Share in such offering); and provided further that that for purposes of the application of Section 5(b) to a Share Distribution consisting solely of equity awards and options under the Company’s board and shareholder approved equity incentive plans, “Market Price” means the Closing Price per Share for the date of such grant.

 

“Person” means an individual, a corporation, a partnership, an association, a trust or any other entity or organization, including a government or political subdivision or an agency or instrumentality thereof.

 

“Requisite Holders” means at any time holders of Warrant Shares and Warrants representing at least a majority of the Warrant Shares outstanding or issuable upon the exercise of all the outstanding Warrants.

 

“Securities Act” means the Securities Act of 1933, as amended, or any successor Federal statute, and the rules and regulations of the Commission thereunder, all as the same shall be in effect at the time.

 

“Shares” means the Company’s currently authorized common stock, New Israeli Shekels 0.01 par value, and stock of any other class or other consideration into which such currently authorized capital stock may hereafter have been changed.

 

“Warrant” means, as the context requires, this warrant and any successor warrant or warrants issued upon a whole or partial transfer or assignment of any such Share purchase warrant or of any such successor warrant.

 

2

 

“Warrant Shares” means the number of Shares issued or issuable upon exercise of this Warrant as set forth in the introduction hereto, as adjusted from time to time pursuant to Section 5, or in the case of other Warrants, issuable upon exercise of those Warrants.

 

(b)                                 Accounting Terms and Determinations. Unless otherwise specified herein, all accounting terms used herein shall be interpreted, all accounting determinations hereunder shall be made, and all financial statements required to be delivered hereunder shall be prepared, in accordance with generally accepted accounting principles. When used herein, the term “financial statements” shall include the notes and schedules thereto. References to fiscal periods are to fiscal periods of the Company.

 

(c)                                  Computation of Time Periods. With respect to the computation of periods of time from a specified date to a later specified date, the word “from” means “from and including” and the words “to” and “until” each mean “to but excluding.” Periods of days shall be counted in calendar days unless otherwise stated.

 

(d)                                 Construction. Unless the context requires otherwise, references to the plural include the singular and to the singular include the plural, references to any gender include any other gender, the part includes the whole, the term “including” is not limiting, and the term “or” has, except where otherwise indicated, the inclusive meaning represented by the phrase “and/or.” The words “hereof,” “herein,” “hereby,” “hereunder,” and similar terms in this Warrant refer to this Warrant as a whole and not to any particular provision of this Warrant. Section, subsection, clause, exhibit and schedule references are to this Warrant, unless otherwise specified. Any reference to this Warrant includes any and all permitted alterations, amendments, changes, extensions, modifications, renewals, or supplements thereto or thereof, as applicable.

 

(e)                                  Exhibits and Schedules. All of the exhibits and schedules attached hereto shall be deemed incorporated herein by reference.

 

(f)                                   No Presumption Against Any Party. Neither this Warrant nor any uncertainty or ambiguity herein or therein shall be construed or resolved using any presumption against any party hereto or thereto, whether under any rule of construction or otherwise. On the contrary, this Warrant has been reviewed by each of the parties and their counsel and, in the case of any ambiguity or uncertainty, shall be construed and interpreted according to the ordinary meaning of the words used so as to fairly accomplish the purposes and intentions of all parties hereto.

 

Section 2.                                           Exercise of Warrant.

 

(a)                                 Exercise Requirements.

 

(i)                                     Notice of Exercise and Payment. The Warrant Holder may exercise this Warrant in whole or in part, at any time or from time to time on any Business Day on or prior to the Expiration Date, by delivering to the Company a duly executed notice (a “Notice of Exercise”) in the form of Exhibit A and by payment to the Company of the Exercise Price per Warrant Share, at the election of the Warrant Holder, either (a) by wire transfer of immediately available funds to the account of the Company in an amount equal to the Exercise Amount, (b) by receiving from the Company the number of Warrant Shares equal to (i) the number of Warrant Shares as to which this Warrant is being exercised minus (ii) the number of Warrant Shares having a value, based on the Closing Price on the trading day immediately prior to the date of such exercise (or if there is no such Closing Price, then based on the Appraised Value as of such day), equal to the Exercise Amount, or (c) any combination of the foregoing. The Company acknowledges that the provisions of clause (b) are intended, in part, to ensure that a full or partial exchange of this Warrant pursuant to such clause (b) will qualify as a conversion, within the meaning of paragraph (d)(3)(iii) of Rule 144 under the Securities Act, and the holding period for the

 

3

 

Warrant Shares shall be deemed to have commenced on the date this Warrant was originally issued to the Warrant Holder. At the request of any Holder, the Company will accept reasonable modifications to the exchange procedures provided for in this Section in order to accomplish such intent. For all purposes of this Warrant (other than this Section 2(a)(i)), any reference herein to the exercise of this Warrant shall be deemed to include a reference to the exchange of this Warrant into Shares in accordance with the terms of clause (b).

 

(ii)                                  Limitations on Exercise. Notwithstanding any provisions herein to the contrary, the Holder shall not be entitled to exercise this Warrant for a number of Warrant Shares in excess of that number of Warrant Shares which, upon giving effect to such exercise, would cause the aggregate number of Company’s securities beneficially owned by the Holder to exceed 24.9% or 44.9% of the outstanding share capital of the Company following such exercise (excluding, for the avoidance of doubt, any shares such Holder may be deemed to beneficially own by reason of holding any Warrants that have not yet been exercised and are not proposed to be exercised at such time of determination)(the “Cap”). The limitation described in the previous sentence (i) will only apply to the extent that exceeding the Cap will trigger a shareholder vote or regulatory approval under Israeli law, but only to the extent that no such shareholder vote or regulatory approval has already been obtained and (ii) will not apply in the event the Company has publicly disclosed that it intends to effect a Corporate Reorganization. Except as set forth in the preceding sentence, for purposes of this Section, beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act, and “group” shall have the meaning set forth in Section 13(d) of the Exchange Act (any such persons or entities with whom the Warrant Holder shall constitute a “group” with respect to the Shares, collectively, the “Attributable Parties”). Notwithstanding the foregoing, to the extent the Cap applies, the determination of whether this Warrant is exercisable (in relation to other securities owned by such Holder) and of which portion of this Warrant is exercisable shall be in the sole discretion of Company. For purposes of determining the number of outstanding Shares the Warrant Holder may acquire upon the exercise of this Warrant without exceeding the Cap, the Warrant Holder may rely on the number of outstanding Shares as reflected in (x) the Company’s most recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q, Current Report on Form 8-K or other public filing with the Commission, as the case may be, (y) a more recent public announcement by the Company or (z) any other written notice by the Company, if any, setting forth the number of Shares outstanding (the “Reported Outstanding Share Number”). For purposes of the foregoing, the aggregate number of Shares beneficially owned by the Warrant Holder and the other Attributable Parties shall include the number of Shares held by the Warrant Holder and all other Attributable Parties plus the number of Shares issuable upon exercise of this Warrant with respect to which the determination of such sentence is being made, but shall exclude Shares which would be issuable upon (A) exercise of the remaining, unexercised portion of this Warrant beneficially owned by the Warrant Holder or any of the other Attributable Parties and (B) exercise or conversion of the unexercised or unconverted portion of any other securities of the Company (including, without limitation, any convertible notes or convertible preferred stock or warrants, including other Warrants) beneficially owned by the Warrant Holder or any other Attributable Party subject to a limitation on conversion or exercise analogous to the limitation contained in this clause (ii). In any case, the number of outstanding Shares shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Warrant Holder and any other Attributable Party since the date as of which the Reported Outstanding Share Number was reported. Upon the written request of the Holder, the Company shall within three trading days confirm in writing (including by electronic mail) to the Holder: (i) the number of Company’s Shares then outstanding, (ii) the Company’s determination of the attainment of the Cap, and (iii) the limitation to exercise hereunder, with respect to which portion of the Warrant is exercisable pursuant to this provision. Any number of Warrant Shares that may not be exercisable because of this Section 2(a)(ii) shall be exercisable at such other time when the exercise thereof shall not cause the number Company’s securities beneficially owned by the Holder to exceed the Cap in accordance with this Section 2(a)(ii); provided that such exercise is before the Expiration Date.

 

4

 

(b)                                 Effectiveness and Delivery. The Company shall in accordance with such Notice of Exercise, (i) as soon as practicable but not later than three Business Days after the Company shall have received such Notice of Exercise and payment, execute an electronic delivery of the Warrant Shares to the Holder’s account at the Depository Trust Company (“DTC”) or a similar organization, or (ii) as soon as practicable but not later than five Business Days after the Company shall have received such Notice of Exercise and payment, execute and deliver or cause to be executed and delivered a certificate or certificates representing, the number of Shares specified in such Notice of Exercise, free of restrictive legends, issued in the name of the Warrant Holder or in such other name or names of any Person or Persons designated in such Notice of Exercise, unless in the case of clause (i) and (ii) a registration statement covering the resale of the Warrant Shares and naming the Holder as a selling stockholder thereunder is not then effective or the Shares are not freely transferable without volume and manner of sale restrictions pursuant to Rule 144 under the Securities Act, in which case the Company shall record, in book entry, the Shares issuable upon such exercise with appropriate restrictive legend. If the Warrant Shares are to be issued free of all restrictive legends, the Company shall, upon the written request of the Warrant Holder, use its reasonable best efforts to deliver, or cause to be delivered, Warrant Shares hereunder electronically through DTC or another established clearing corporation performing similar functions, if available. This Warrant shall be deemed to have been exercised and such Share certificate or certificates, or such book entry or book entries, shall be deemed to have been issued, and the Warrant Holder or other Person or Persons designated in such Notice of Exercise shall be deemed for all purposes to have become a holder of record of Shares, all as of the date that such Notice of Exercise and payment shall have been received by the Company. To the maximum extent permitted by law, the Company’s obligations to issue and deliver Warrant Shares in accordance with and subject to the terms hereof are not conditioned upon or impaired by any action or inaction by the Warrant Holder to enforce the same, any waiver or consent with respect to any provision hereof, the recovery of any judgment against any Person or any action to enforce the same, or any setoff, counterclaim, recoupment, limitation or termination, or any breach or alleged breach by the Warrant Holder or any other Person of any obligation to the Company or any violation or alleged violation of law by the Warrant Holder or any other Person, and irrespective of any other circumstance that might otherwise limit such obligation of the Company to the Warrant Holder in connection with the issuance of Warrant Shares. Nothing herein shall limit the Warrant Holder’s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company’s failure to timely deliver certificates, or record book entries, representing the Warrant Shares issuable upon exercise of the Warrant as required pursuant to the terms hereof.

 

(c)                                  Surrender of Warrant. The Warrant Holder shall surrender this Warrant to the Company when it delivers the Notice of Exercise, and in the event of a partial exercise of the Warrant, the Company shall execute and deliver to the Warrant Holder, at the time the Company delivers the Share certificate or certificates, or records a book entry or book entries, for Shares issued pursuant to such Notice of Exercise, a new Warrant for the unexercised portion of the Warrant, but in all other respects identical to this Warrant.

 

(d)                                 Legend. Each certificate or book entry for Warrant Shares issued upon exercise of this Warrant, unless at the time of exercise such Warrant Shares are registered under the Securities Act, shall bear the following legend:

 

THIS SECURITY HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FILED UNDER SAID ACT AND ANY APPLICABLE STATE SECURITIES LAWS, UNLESS AN EXEMPTION FROM SUCH REGISTRATION IS AVAILABLE.

 

5

 

Any certificate or book entry for Warrant Shares issued at any time in exchange or substitution for any Shares, a certificate or book entry for which bears such legend (unless at that time such Warrant Shares are registered under the Securities Act), shall also bear such legend unless, in the written opinion of counsel selected by the holder of such certificate or book entry (who may be an employee of such holder), which counsel and opinion shall be reasonably acceptable to the Company, the Warrant Shares represented thereby need no longer be subject to restrictions on resale under the Securities Act.

 

(e)                                  Fractional Shares. The Company shall not be required to issue fractions of Shares upon an exercise of the Warrant. If any fraction of a Share would, but for this restriction, be issuable upon an exercise of the Warrant, in lieu of delivering such fractional Share, the Company shall pay to the Warrant Holder, in cash, an amount equal to the same fraction times the Closing Price on the trading day immediately prior to the date of such exercise (or if there is no such Closing Price, then based on the Appraised Value as of such day).

 

(f)                                   Expenses and Taxes. The Company shall pay all expenses, taxes and owner charges payable in connection with the preparation, issuance and delivery of certificates or recordation of book entries for the Warrant Shares and any new Warrants, except that if the certificates or book entries for the Warrant Shares or the new Warrants are to be registered in a name or names other than the name of the Warrant Holder, funds sufficient to pay all transfer taxes payable as a result of such transfer, shall be paid by the Warrant Holder at the time of its delivery of the Notice of Exercise or promptly upon receipt of a written request by the Company for payment.

 

(g)                                  Automatic Cashless Exercise. To the extent that there has not been an exercise by the Warrant Holder pursuant to Section 2(a) hereof, any portion of the Warrant that remains unexercised shall be exercised automatically in whole (not in part), upon the Expiration Date. Payment by the Warrant Holder upon such automatic exercise shall be in the form of the Warrant Holder receiving from the Company the number of Warrant Shares equal to (i) the number of Warrant Shares as to which this Warrant is being automatically exercised minus (ii) the number of Warrant Shares having a value, based on the Closing Price on the trading day immediately prior to the date of such automatic exercise (or if there is no such Closing Price, then based on the Appraised Value as of such day), equal to the Exercise Amount.

 

(h)                                 Buy-In. If by the close of the third (3rd) Business Day after delivery of a Notice of Exercise and the payment of the aggregate exercise price for all or any part of this Warrant, the Company fails to deliver to the Warrant Holder a book entry record, under the name of the Warrant Holder, representing the required number of Warrant Shares in the manner required pursuant to Section 2(b), and if after such third (3rd) Business Day and prior to the receipt of such Warrant Shares, the Warrant Holder purchases (in an open market transaction or otherwise) Shares to deliver in satisfaction of a sale by the Warrant Holder of the Warrant Shares which the Warrant Holder anticipated receiving upon such exercise (a “Buy-In”), then the Company shall, within three (3) Business Days after the Warrant Holder’s request and in the Warrant Holder’s sole discretion, either (1) pay in cash to the Warrant Holder an amount equal to the Warrant Holder’s total purchase price (including brokerage commissions, if any) for the Shares so purchased, at which point the Company’s obligation to deliver such certificate or record such book entry (and to issue such Warrant Shares) shall terminate or (2) promptly honor its obligation to deliver to the Warrant Holder a book entry record, under the name of the Warrant Holder, representing such Warrant Shares and pay cash to the Warrant Holder in an amount equal to the excess (if any) of the Warrant Holder’s total purchase price (including brokerage commissions, if any) for the Shares so purchased in the Buy-In over the product of (A) the number of Shares purchased in the Buy-In, times (B) the Closing Price of a Share on the Exercise Date.

 

6

 

Section 3.                                           Investment Representation. By accepting the Warrant, the Warrant Holder represents that it is acquiring the Warrant for its own account for investment purposes and not with the view to any sale or distribution, that the Warrant Holder will not offer, sell or otherwise dispose of the Warrant or the Warrant Shares except under circumstances as will not result in a violation of applicable securities laws, and that the Warrant Holder is an “accredited investor” as that term is defined in Rule 501 under the Securities Act.

 

Section 4.                                           Validity of Warrant and Issuance of Shares.

 

(a)                                 The Company represents and warrants that this Warrant has been duly authorized, is validly issued, and constitutes the valid and binding obligation of the Company.

 

(b)                                 The Company further represents and warrants that on the date hereof it is duly authorized and reserved, and the Company hereby agrees that it will at all times until the Expiration Date have duly authorized and reserved, such number of Shares as will be sufficient to permit the exercise in full of the Warrant, and that all such Shares are and will be duly authorized and, when issued upon exercise of the Warrant, will be validly issued, fully paid and non-assessable, and free and clear of all security interests, claims, liens, equities and other encumbrances.

 

Section 5.                                           Antidilution Provisions. The Exercise Price in effect at any time, and the number of Warrant Shares that may be purchased upon any exercise of the Warrant, shall be subject to change or adjustment as follows:

 

(a)                                 Share Reorganization. If the Company shall subdivide its outstanding Shares into a greater number of Shares, by way of a stock split, stock dividend or otherwise, or consolidate its outstanding Shares into a smaller number of Shares (any such event being herein called a “Share Reorganization”), then (i) the Exercise Price shall be adjusted, effective immediately after the effective date of such Share Reorganization, to a price determined by multiplying the Exercise Price in effect immediately prior to such effective date by a fraction, the numerator of which shall be the number of Shares outstanding on such effective date before giving effect to such Share Reorganization and the denominator of which shall be the number of Shares outstanding after giving effect to such Share Reorganization, and (ii) the number of Shares subject to purchase upon exercise of this Warrant shall be adjusted, effective at such time, to a number determined by multiplying the number of Shares subject to purchase immediately before such Share Reorganization by a fraction, the numerator of which shall be the number of Shares outstanding after giving effect to such Share Reorganization and the denominator of which shall be the number of Shares outstanding immediately before giving effect to such Share Reorganization.

 

(b)                                 Share Distribution.

 

(i)                                     If the Company shall issue, sell or otherwise distribute any Shares (including, for the avoidance of doubt, any deemed issuance, sale or distribution described in paragraphs (ii) and (iii) below), other than pursuant to a Share Reorganization (which is governed by Section 5(a)) (any such event, including any event described in paragraphs (ii) and (iii) below, being herein called a “Share Distribution”), for a consideration per Share less than (x) the Market Price immediately prior to such Share Distribution or (y) the Exercise Price then in effect, then, effective upon such Share Distribution, the Exercise Price shall be reduced to a price determined by multiplying the Exercise Price by a fraction, the numerator of which shall be the sum of (A) the number of Shares outstanding immediately prior to such Share Distribution multiplied by the higher of such Market Price and the Exercise Price, plus (B) the consideration, if any, received by the Company upon such Share Distribution, and the denominator of which shall be the product of (1) the total number of Shares outstanding immediately after such Share Distribution multiplied by (2) the higher of such Market Price and the Exercise Price. If any Share

 

7

 

Distribution shall require an adjustment to the Exercise Price pursuant to the foregoing provisions of this Section 5(b), including by operation of paragraph (ii) or (iii) below, then, effective at the time such adjustment is made, the number of Shares subject to purchase upon exercise of this Warrant shall be increased to a number determined by multiplying the number of Shares subject to purchase immediately before such Share Distribution by a fraction, the numerator of which shall be the Exercise Price in effect immediately prior to such event and the denominator of which shall be the Exercise Price as adjusted in accordance with this Section 5(b). The provisions of this Section 5(b), including by operation of paragraph (ii) or (iii) below, shall not operate to increase the Exercise Price or reduce the number of Shares subject to purchase upon exercise of this Warrant.

 

(ii)                                  If the Company shall issue, sell, distribute or otherwise grant in any manner (including by assumption) any rights to subscribe for or to purchase, or any warrants or options for the purchase of Shares or any securities convertible into or exchangeable for Shares (such rights, warrants or options being herein called “Options” and such convertible or exchangeable securities being herein called “Convertible Securities”), whether or not such Options or the rights to convert or exchange any such Convertible Securities in respect of such Options are immediately exercisable or exercisable prior to the Expiration Date or thereafter, and the price per Share for which Shares are issuable upon the exercise of such Options or upon conversion or exchange of such Convertible Securities in respect of such Options (determined by dividing (x) the aggregate amount, if any, received or receivable by the Company as consideration for the granting of such Options, plus the minimum aggregate amount of additional consideration payable to the Company upon the exercise of all such Options, plus, in the case of Options to acquire Convertible Securities, the minimum aggregate amount of additional consideration, if any, payable upon issuance or sale of such Convertible Securities and upon the conversion or exchange thereof, by (y) the total maximum number of Shares issuable upon the exercise of such Options or upon the conversion or exchange of all such Convertible Securities issuable upon the exercise of such Options) shall be less than (A) the Market Price immediately prior to the granting of such Options or (B) the Exercise Price, then, for purposes of Section 5(b)(i), the total maximum number of Shares issuable upon the exercise of such Options or upon conversion or exchange of the total maximum amount of such Convertible Securities issuable upon the exercise of such Options shall be deemed to have been issued as of the date of granting of such Options and thereafter shall be deemed to be outstanding and the Company shall be deemed to have received as consideration of such price per Share, determined as provided above, therefor. Except as otherwise provided in paragraph (iv) below, no additional adjustment of the Exercise Price shall be made upon the actual exercise of such Options or upon conversion or exchange of such Convertible Securities.

 

(iii)                               If the Company shall issue, sell or otherwise distribute (including by assumption) any Convertible Securities, whether or not the rights to exchange or convert thereunder are immediately exercisable or exercisable prior to the Expiration Date or thereafter, and the price per Share for which Shares are issuable upon the conversion or exchange of such Convertible Securities (determined by dividing (x) the aggregate amount received or receivable by the Company as consideration for the issuance, sale or distribution of such Convertible Securities, plus the minimum aggregate amount of additional consideration, if any, payable to the Company upon the conversion or exchange thereof, by (y) the maximum number of Shares issuable upon the conversion or exchange of all such Convertible Securities) shall be less than (A) the Market Price immediately prior to such issuance, sale or distribution or (B) the Exercise Price, then, for purposes of Section 5(b)(i), the total maximum number of Shares issuable upon conversion or exchange of all such Convertible Securities shall be deemed to have been issued as of the date of the issuance, sale or distribution of such Convertible Securities thereafter shall be deemed to be outstanding and the Company shall be deemed to have received as consideration such price per Share, determined as provided above, therefor. Except as otherwise provided in paragraph (iv) below, no additional adjustment of the Exercise Price shall be made upon the actual conversion or exchange of such Convertible Securities.

 

8

 

(iv)                              If (x) the purchase price provided for in any Option referred to in Section 5(b)(ii) or the additional consideration, if any, payable upon the conversion or exchange of any Convertible Securities referred to in Sections 5 (b)(ii) or 5(b)(iii) or the rate at which any Convertible Securities referred to in Sections 5(b)(ii) or 5(b)(iii) are convertible into or exchangeable for Shares shall change at any time (other than under or by reason of provisions designed to protect against dilution upon an event which results in a related adjustment pursuant to this Section 5), or (y) any of such Options or Convertible Securities shall have terminated, lapsed or expired, the Exercise Price then in effect shall forthwith be readjusted (effective only with respect to any exercise of this Warrant after such readjustment) to the Exercise Price which would then be in effect had the adjustment made upon the issuance, sale, distribution or grant of such Options or Convertible Securities been made based upon such changed purchase price, additional consideration or conversion rate, as the case may be (in the case of any event referred to in clause (x) of this paragraph (iv)) or had such adjustment not been made (in the case of any event referred to in clause (y) of this paragraph (iv)).

 

(v)                                 If the Company shall pay a dividend or make any other distribution upon any capital stock of the Company payable in Shares, Options or Convertible Securities, other than pursuant to a Share Reorganization (which is governed by Section 5(a)), then, for purposes of this Section 5(b), such Shares, Options or Convertible Securities shall be deemed to have been issued or sold without consideration.

 

(vi)                              If any Shares, Options or Convertible Securities shall be issued, sold or distributed for cash, the consideration received therefor shall be deemed to be the amount received by the Company therefore, less any expenses in excess of reasonable and customary expenses in connection therewith. If any Shares, Options or Convertible Securities shall be issued, sold or distributed for a consideration other than cash, the amount of the consideration other than cash received by the Company shall be deemed to be the fair market value of such consideration at the time of its receipt by the Company as determined in good faith by the Board of Directors of the Company, less any expenses in excess of reasonable and customary expenses incurred in connection therewith. If any Shares, Options or Convertible Securities shall be issued in connection with any merger in which the Company is the surviving entity, the amount of consideration therefore shall be deemed to be the fair market value of such portion of the assets and business of the non-surviving entity as shall be attributable to such Shares, Options or Convertible Securities, as the case may be, at the time of the merger as determined in good faith by the Board of Directors of the Company (in making such determination the members of its Board of Directors may give effect to the proposed acquisition and incorporate the prospects of the performance of the assets and business of the non-surviving corporation over the twelve (12) month period following the acquisition, including any reasonably demonstrate synergistic or value enhancing factors). If any Options shall be issued in connection with the issuance and sale of other securities of the Company, together comprising one integral transaction in which no specific consideration is allocated to such Options by the parties thereto, such Options shall be deemed to have been issued without consideration.

 

(c)                                  Special Distributions; Above Market Purchases of Securities.

 

(i)                                     If the Company shall issue or distribute to any holder or holders of Shares evidences of indebtedness, any other securities of the Company or any cash, property or other assets (excluding (i) a Share Reorganization and (ii) a Share Distribution), whether or not accompanied by a purchase, redemption or other acquisition of Shares (any such nonexcluded event being herein called a “Special Distribution”), then the Warrant Holder shall be entitled to a pro-rata Share of such Special Distribution as though the Warrant Holder had fully exercised this Warrant immediately prior to the record date for such Special Distribution, and the Company shall pay or distribute such pro-rata share to the Warrant Holder when paid or distributed to the holders of the Shares, or the Warrant Holder may at its option decline to accept such payment or distribution in which case the (x) the Exercise Price shall be

 

9

 

decreased, effective immediately after the effective date of such Special Distribution, to a price determined by multiplying the Exercise Price then in effect by a fraction, the numerator of which shall be the Market Price immediately prior to such effective date less any cash and the then fair market value, as determined in good faith by the Board of Directors of the Company, of any evidences of indebtedness, securities or property or other assets issued or distributed in such Special Distribution with respect to one Share, and the denominator of which shall be the Market Price immediately prior to such effective date, and (y) the number of Shares subject to purchase upon exercise of this Warrant shall be increased to a number determined by multiplying the number of Shares subject to purchase immediately before such Special Distribution by a fraction, the numerator of which shall be the Exercise Price in effect immediately before such Special Distribution and the denominator of which shall be the Exercise Price in effect immediately after such Special Distribution. A reclassification of the Shares (other than a change in par value, or from par value to no par value or from no par value to par value) into shares of any other class of stock shall be deemed to be a distribution by the Company to the holders of its Shares of such class of stock and, if the outstanding Shares shall be changed into a larger or smaller number of Shares as part of such reclassification, a Share Reorganization.

 

(ii)                                  If, at any time after the date hereof, the Company or any Subsidiary shall repurchase (a “Repurchase”), by self-tender offer or otherwise, any securities of the Company at an aggregate repurchase price that exceeds the aggregate Market Price for the securities repurchased determined as of the Business Day immediately prior to the earliest of (i) the date of such Repurchase, (ii) the commencement of an offer to repurchase or (iii) the public announcement of either (such date being referred to as the “Determination Date”), then the Exercise Price and the number of Warrant Shares issuable upon exercise of this Warrant shall be adjusted as follows:

 

(A)                               The Exercise Price shall be reduced to an amount equal to the product of (A) the Exercise Price in effect immediately prior to such issuance or sale times (B) a fraction, (I) the numerator of which shall be (x) the product of (1) the Market Price for the Shares as of the Determination Date times (2) the number of Shares outstanding immediately following the consummation of the Repurchase less (y) the Repurchase Premium (as defined below), and (II) the denominator of which shall be (x) the product of (1) the Market Price for the Shares as of the Determination Date times (2) the number of Shares outstanding immediately following the consummation of the Repurchase.

 

(B)                               The number of Warrant Shares issuable upon exercise of this Warrant shall be increased to the number of Shares determined by multiplying (x) the number of Warrant Shares issuable upon exercise of this Warrant immediately prior to such distribution times (y) a fraction (1) the numerator of which shall be the Exercise Price in effect immediately prior to the adjustment in clause (A) of this Section 5(c)(ii) and (2) the denominator of which shall be the Exercise Price in effect immediately after such adjustment.

 

The amount by which the aggregate repurchase price for all securities repurchased in any Repurchase (including for such purposes any fees or other direct or indirect consideration payable in connection therewith) exceeds the aggregate Market Price for such securities is referred to as the “Repurchase Premium.”

 

(d)                                 Corporate Reorganization. Without limiting any of the other provisions hereof, if any (i) capital reorganization; (ii) reclassification of the capital stock of the Company or compulsory share exchange pursuant to which the Shares are effectively converted into or exchanged for other securities, cash or property; (iii) merger, consolidation, reorganization or other similar transaction or series of related transactions which results in the Shares of the Company outstanding immediately prior thereto representing immediately thereafter (either by remaining outstanding or by being converted into voting securities of the surviving or acquiring entity) less than 50% of the combined voting power and economic

 

10

 

interests in the Company or such surviving or acquiring entity outstanding immediately after such transaction; (iv) sale, lease, license, transfer, conveyance or other disposition of all or substantially all of the assets of the Company and its subsidiaries taken as a whole; (v) sale of shares of capital stock of the Company, in a single transaction or series of related transactions, representing at least 35% of the voting power of the voting securities of or economic interests in the Company; (vi) acquisition by any “person” (together with his, her or its Affiliates) or “group” (within the meaning of Section 13(d) or 14(d) of the Exchange Act), directly or indirectly, of the beneficial ownership (as such term is defined in Rule 13d-3 promulgated under the Exchange Act) of outstanding Shares and/or other equity securities of the Company, in a single transaction or series of related transactions (including, without limitation, one or more tender offers or exchange offers), representing 35% or more of the voting power of or economic interests in the then outstanding shares of capital stock of the Company, (vii) tender offer or exchange offer (whether by the Company or another Person) pursuant to which all or substantially all of the holders of Shares are permitted to tender or exchange their shares for other securities, cash or property (each of (i)-(vii) above a “Corporate Reorganization”) shall be effected, then the Company shall use its best efforts to ensure that lawful and adequate provision shall be made whereby each Warrant Holder shall thereafter continue to have the right to purchase and receive upon the basis and upon the terms and conditions herein specified and in lieu of the Warrant Shares issuable upon exercise of the Warrants held by such Warrant Holder (without regard to any limitations on exercise contained in such Warrants), shares of voting stock in such successor entity, surviving entity or entity purchasing or otherwise acquiring such assets in the Corporate Reorganization (as the case may be, the “Acquirer”), such that the aggregate value of the Warrant Holder’s warrants to purchase such number of shares of the Acquirer (where the value of a warrant to purchase one share in the Acquirer is determined in accordance with the Black-Scholes Option Pricing formula set forth in Appendix (A) hereto) is equivalent to the aggregate value of the Warrants held by such Warrant Holder (where the value of each Warrant to purchase one share in the Company is determined in accordance with the Black-Scholes Option Pricing formula set forth Appendix (B) hereto). Furthermore, the new warrants to purchase shares in the Acquirer referred to herein shall have the same expiration date as the Warrants, and shall have a strike price, KAcq, that is calculated in accordance with Appendix (A) hereto. For the avoidance of doubt, if the successor, surviving or acquiring entity, as the case may be, is a member of a consolidated group for financial reporting purposes, the “Acquirer” shall be deemed to be the parent of such consolidated group for purposes of this Section 5(d) and Appendix (A) hereto.

 

Moreover, appropriate provision shall be made with respect to the rights and interests of each Warrant Holder to the end that the provisions hereof (including, without limitation, provision for adjustment of the Warrant Price) shall thereafter be applicable, as nearly equivalent as may be practicable in relation to any shares of stock thereafter deliverable upon the exercise thereof. The Company shall not effect any such Corporate Reorganization unless prior to or simultaneously with the consummation thereof the successor corporation resulting from such consolidation or merger, or the corporation purchasing or otherwise acquiring such assets or other appropriate corporation or entity shall assume by written instrument, reasonably deemed by the Board of Directors of the Company and the Requisite Holders to be satisfactory in form and substance, the obligation to deliver to the holder of the Warrants, at the last address of such holder appearing on the books of the Company, such shares of stock, as, in accordance with the foregoing provisions, such holder may be entitled to purchase, and the other obligations under these Warrants. The provisions of this Section 5(d) shall similarly apply to successive Corporate Reorganizations. Notwithstanding anything to the contrary hereunder, if the Corporate Reorganization, is (1) a transaction where the consideration paid to the holders of the Shares consists of cash, (2) a “Rule 13e-3 transaction” as defined in Rule 13e-3 under the Securities Exchange Act of 1934, as amended, or (3) a Corporate Reorganization involving a person or entity not traded on the New York Stock Exchange, the NYSE Alternext (formerly the American Stock Exchange), the NASDAQ Global Select Market, the NASDAQ Global Market or the NASDAQ Capital Market, at the request of the Warrant Holder delivered before the ninetieth (90th) day after such Corporate Reorganization, the

 

11

 

Company (or the Acquirer) shall purchase this Warrant from the Warrant Holder by paying to the Warrant Holder, within five (5) Business Days after such request (or, if later, on the effective date of the Corporate Reorganization), cash in an amount equal to the aggregate value of this Warrant, where the value of each Warrant to purchase one Warrant Share is calculated in accordance with the Black-Scholes Option Pricing formula set forth in Appendix (B) hereto.

 

(e)                                  Adjustment Rules.

 

(i)                                     Any adjustments pursuant to this Section 5 shall be made successively whenever any event referred to herein shall occur, except that, notwithstanding any other provision of this Section 5, no adjustment shall be made to the number of Warrant Shares to be delivered to the Warrant Holder (or to the Exercise Price) if such adjustment represents less than 1% of the number of Warrant Shares previously required to be so delivered, but any lesser adjustment shall be carried forward and shall be made at the time and together with the next subsequent adjustment which together with any adjustments so carried forward shall amount to 1% or more of the number of Warrant Shares to be so delivered.

 

(ii)                                  No adjustments shall be made pursuant to this Section 5 in respect of the issuance of Warrant Shares upon exercise of the Warrant;

 

(iii)                               If the Company shall take a record of the holders of its Shares for any purpose referred to in this Section 5, then (x) such record date shall be deemed to be the date of the issuance, sale, distribution or grant in question and (y) if the Company shall legally abandon such action prior to effecting such action, no adjustment shall be made pursuant to this Section 5 in respect of such action.

 

(iv)                              In computing adjustments under this Section 5, (A) fractional interests in Shares shall be taken into account to the nearest one-thousandth of a Share, and (B) calculations of the Exercise Price shall be carried to the nearest one-thousandth of one cent.

 

(v)                                 Notwithstanding anything herein to the contrary, no adjustment pursuant to this Section 5 shall cause the aggregate Exercise Price for all of the Warrant Shares to increase to more than $100.00.

 

(f)                                   Proceedings Prior to Any Action Requiring Adjustment. As a condition precedent to the taking of any action which would require an adjustment pursuant to this Section 5, the Company shall take any action which may be necessary, including obtaining regulatory approvals or exemptions, in order that the Company may thereafter validly and legally issue as fully paid and nonassessable all Shares which the Warrant Holder is entitled to receive upon exercise of the Warrant.

 

(g)                                  Notice of Adjustment. Not less than 10 days prior to the record date or effective date, as the case may be, of any action which requires or might require an adjustment or readjustment pursuant to this Section 5, the Company shall give notice to the Warrant Holder of such event, describing such event in reasonable detail and specifying the record date or effective date, as the case may be, and, if determinable, the required adjustment and computation thereof. If the required adjustment is not determinable as the time of such notice, the Company shall give notice to the Warrant Holder of such adjustment and computation as soon as reasonably practicable after such adjustment becomes determinable. In connection with any such adjustment or readjustment, at its sole cost and expense, the Company will also cause independent certified public accountants of recognized national standing (which may be the regular auditors of the Company) selected by the Company to verify its computations and, in connection with the preparation of the Company’s quarterly financial statements prepare a report setting forth such adjustment or readjustment and showing in reasonable detail the method of calculation thereof and the facts upon which such adjustment or readjustment is based, including a statement of (i) the consideration received or to be received by the Company for any Share Distribution issued or sold or

 

12

 

deemed to have been issued, (ii) the number of Shares outstanding or deemed to be outstanding, and (iii) the Exercise Price in effect immediately prior to such issue or sale and as adjusted and readjusted (if required by this Section 5) on account thereof. The Company will forthwith mail a copy of each such report to the Warrant Holder and will, upon the written request at any time of the Warrant Holder, furnish to such holder a like report setting forth the Exercise Price at the time in effect and showing in reasonable detail how it was calculated. The Company will also keep copies of all such reports at its office and will cause the same to be available for inspection at such office during normal business hours by the Warrant Holder or any prospective purchaser of this Warrant designated by the Warrant Holder.

 

(h)                                 Subsequent Warrants. Irrespective of any adjustments in the Exercise Price or the number of Warrant Shares issuable upon exercise of the Warrants theretofore or thereafter issued may continue to express the same Exercise Price per Share and number and kind of Warrant Shares as are stated in this Warrant.

 

(i)                                     Disputes. Any dispute which arises between the Warrant Holder and the Company with respect to the calculation of the adjusted Exercise Price or Warrant Shares issuable upon exercise shall be determined by the independent auditors of the Company, and such determination shall be binding upon the Company and the holders of the Warrants and the Warrant Shares if made in good faith and without manifest error.

 

(j)                                    Other Actions Affecting Shares.

 

(i)                                     Equitable Equivalent. In case any event shall occur as to which the provisions of this Section 5 set forth above hereof are not strictly applicable but the failure to make any adjustment would not, in the opinion of the Warrant Holder, fairly protect the purchase rights represented by this Warrant in accordance with the essential intent and principles of this Section 5, then, in each such case, at the request of the Warrant Holder, the Company shall appoint a firm of independent investment bankers mutually agreed by the Company and the Warrant Holder (which shall be completely independent of the Company and shall be satisfactory to the holder or the Requisite Holders), which shall give their opinion upon the adjustment, if any, on a basis consistent with the essential intent and principles established in this Section 5, necessary to preserve, without dilution, the purchase rights represented by this Warrant. Upon receipt of such opinion, the Company will promptly mail a copy thereof to the holder of this Warrant and shall make the adjustments described therein. The costs of engagement of such investment bank for the purposes of this section shall be paid by the Company.

 

(ii)                                  No Avoidance. The Company shall not, by amendment of its certificate of incorporation or by-laws or through any consolidation, merger, reorganization, transfer of assets, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such action as may be necessary or appropriate in order to protect the rights of the holder of this Warrant against dilution or other impairment as if the holder was a shareholder of the Company entitled to the benefit of fiduciary duties afforded to shareholders under Delaware law. Without limiting the generality of the foregoing, the Company will (a) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior to such increase in par value, (b) take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant, and (c) use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof as may be necessary to enable the Company to perform its obligations under this Warrant.

 

(k)                                 Calculation of Consideration Received. The consideration for the issue or sale of any Share Distribution shall, irrespective of the accounting treatment of such consideration:

 

13

 

(i)                                     insofar as it consists of cash, be computed at the amount of cash actually received by the Company without reduction for any expenses paid or incurred by the Company or any commissions or compensations paid or concessions or discounts allowed to underwriters, dealers or others performing similar services in connection with such issue or sale;

 

(ii)                                  insofar as it consists of property (including securities) other than cash actually received by the Company, be computed at the Appraised Value thereof at the time of such issue or sale; and

 

(iii)                               insofar as it consists neither of cash nor of other property, be computed as having no value.

 

(l)                                     Adjustment of Par Value. If for any reason (including the operation of the adjustment provisions set forth in this Warrant), the Exercise Price on any date of exercise of this Warrant shall not be lawful and adequate consideration for the issuance of the relevant Warrant Shares, then the Company shall take such steps as are necessary (including the amendment of its certificate of incorporation so as to reduce the par value of the Shares) to cause such Exercise Price to be adequate and lawful consideration on the date the payment thereof is due, but if the Company shall fail to take such steps, then the Company acknowledges that the Warrant Holder shall have been damaged by the Company in an amount equal to an amount, which, when added to the total Exercise Price for the relevant Warrant Shares, would equal lawful and adequate consideration for the issuance of such Warrant Shares, and the Company irrevocably agrees that if the Warrant Holder shall then forgive the right to recover such damages from the Company, such forgiveness shall constitute, and Company shall accept such forgiveness as, additional lawful consideration for the issuance of the relevant Warrant Shares.

 

(m)                             Appraisal.

 

(i)                                     If the Requisite Holders shall, for any reason whatsoever, disagree with the Company’s determination of the Appraised Value of a Share, then such holders shall by notice to the Company (an “Appraisal Notice”) given within sixty (60) days after the Company notifies the holders of such determination, elect to dispute such determination, and such dispute shall be resolved as set forth in clause (ii) of this Section.

 

(ii)                                  The Company shall within ten (10) days after an Appraisal Notice shall have been given, engage an independent investment bank of national repute (the “Appraiser”) selected by the Requisite Holders and retained pursuant to an engagement letter between the Company and the Appraiser with respect to such valuation in form and substance reasonably acceptable to Requisite Holders, to make an independent determination of the Appraised Value of a Share; such value shall be determined without deduction for (a) liquidity considerations, (b) minority shareholder status, or (c) any liquidation or other preference or any right of redemption in favor of any other equity securities of the Company. The costs of engagement of such investment bank for any such determination of Appraised Value shall be paid by the Company.

 

Section 6.                                           Registration Rights and Extension of Expiration Date. The Warrant Holder is entitled to the benefit of certain registration rights with respect to the Warrant Shares as provided in the Subscription Agreement, dated as of July 29, 2016, by and between the Company and the Participants (as defined therein), including the Warrant Holder (the “Subscription Agreement”), and any subsequent holder hereof shall be entitled to such rights to the extent provided in the Subscription Agreement. If the Company fails to cause any Registration Statement covering “Registrable Securities” (as that term is defined in the Subscription Agreement) to be declared effective prior to the applicable dates set forth therein, or if an Event as specified in Section 9.3 of the Subscription Agreement occurs and continues, in each case, for more than thirty (30) days in any twelve (12) month period, or for more than a total of

 

14

 

ninety (90) days, then the Expiration Date of this Warrant shall be extended one day for each day beyond the thirty (30) day or ninety (90) day limits, as the case may be, that the Event continues.

 

Section 7.                                           Transfer of Warrant. The Warrant Holder upon transfer of the Warrant must deliver to the Company a duly executed Warrant Assignment in the form of Exhibit B and upon surrender of this Warrant to the Company, the Company shall execute and deliver a new Warrant with appropriate changes to reflect such Assignment, in the name or names of the assignee or assignees specified in the Warrant Assignment or other instrument of assignment and, if the Warrant Holder’s entire interest is not being transferred or assigned, in the name of the Warrant Holder, and upon the Company’s execution and delivery of such new Warrant, this Warrant shall promptly be cancelled; and provided that any assignee shall have all of the rights of an Initial Holder hereunder. The Company shall pay any transfer tax imposed in connection with such assignment (if any). Any transfer or exchange of this Warrant shall be without charge to the Warrant Holder (except as provided above with respect to transfer taxes, if any) and any new Warrant issued shall be dated the date hereof.

 

Section 8.                                           Assistance in Disposition of Warrant or Warrant Shares. Notwithstanding any other provision herein, in the event that it becomes unlawful for the Warrant Holder to continue to hold the Warrant, in whole or in part, or some or all of the Shares held by it, or restrictions are imposed on any the Warrant Holder by any statute, regulation or governmental authority which, in the judgment of the Warrant Holder, make it unduly burdensome to continue to hold the Warrant or such Shares, the Warrant Holder may sell or otherwise dispose of the Warrant (subject to the restrictions on transfer provided in Section 7) or its Shares, and the Company agrees to provide reasonable assistance to the Warrant Holder in disposing of the Warrant and such Shares in a prompt and orderly manner and, at the request of the Warrant Holder, to provide (and authorize the Warrant Holder to provide) financial and other information concerning the Company to any prospective purchaser of the Warrant or Shares owned by the Warrant Holder.

 

Section 9.                                           Identity of Transfer Agent. The Transfer Agent for the Common Stock is Continental Stock Transfer & Trust Company. Upon the appointment of any subsequent transfer agent for the Shares, the Company will mail to the Warrant Holder a statement setting forth the name and address of such transfer agent.

 

Section 10.                                    Covenants. The Company agrees that:

 

(a)                                 Securities Filings; Rules 144 & 144A. The Company will (i) file any reports required to be filed by it under the Securities Act, the Exchange Act or the rules and regulations adopted by the Commission thereunder, (ii) use its best efforts to cooperate with the Warrant Holder and each holder of Warrant Shares in supplying such information concerning the Company as may be necessary for the Warrant Holder or holder of Warrant Shares to complete and file any information reporting forms currently or hereafter required by the Commission as a condition to the availability of an exemption from the Securities Act for the sale of any Warrants or Warrant Shares, (iii) take such further action as the Warrant Holder may reasonably request to the extent required from time to time to enable the Warrant Holder to sell Warrant Shares without registration under the Securities Act within the limitation of the exemptions provided by Rule 144 or 144A under the Securities Act, as such Rules may be amended from time to time, or any similar rule or regulation hereafter adopted by the Commission, and (iv) upon the request of the Warrant Holder, deliver to the Warrant Holder a written statement as to whether it has complied with such reporting requirements; provided that this subsection (a) shall not require the Company to make any filing under the Securities Act or Exchange Act which the Company is not otherwise obligated to make.

 

(b)                                 Obtaining of Governmental Approvals and Stock Exchange Listings. The Company will, at its own expense, (i) obtain and keep effective any and all permits, consents and approvals of

 

15

 

governmental agencies and authorities which may from time to time be required of the Company in order to satisfy its obligations hereunder, and (ii) take all action which may be necessary so that the Warrant Shares, immediately upon their issuance upon the exercise of the Warrants, will be listed on each securities exchange, if any, on which the Shares are then listed.

 

(c)                                  Structural Dilution. So long as this Warrant remains outstanding, the Company shall not permit any of its Subsidiaries to issue, sell, distribute or otherwise grant in any manner (including by assumption) any rights to subscribe for or to purchase, or any warrants or options for the purchase of any equity securities of such Subsidiary or any securities convertible into or exchangeable for such equity securities (or any rights to subscribe for or to purchase, or any warrants or options for the purchase of any such convertible or exchangeable securities), whether or not immediately exercisable or exercisable prior to the Expiration Date or thereafter.

 

(d)                                 Notices Of Corporate Action. In the event of:

 

(i)                                     any taking by the Company of a record of the holders of any class of securities for the purpose of determining the holders thereof who are entitled to receive any distribution, or any right to subscribe for, purchase or otherwise acquire any Shares or any other securities or property, or to receive any other right, or

 

(ii)                                  any capital reorganization of the Company, any reclassification or recapitalization of the capital stock of the Company, any consolidation or merger involving the Company and any other Person or any transfer of all or substantially all the assets of the Company to any other Person, or any Corporate Reorganization, or

 

(iii)                               any voluntary or involuntary dissolution, liquidation or winding-up of the Company,

 

the Company will mail to the Warrant Holder a notice specifying (i) the date or expected date on which any such record is to be taken for the purpose of such dividend, distribution or right, and the amount and character of such dividend, distribution or right, (ii) the date or expected date on which any such reorganization, reclassification, recapitalization, consolidation, merger, transfer, dissolution, liquidation or winding-up is to take place, and (iii) the time, if any such time is to be fixed, as of which the holders of record of Shares (or other securities under Section 5(d)) shall be entitled to exchange their Shares (or other securities under Section 5(d)) for the securities or other property deliverable upon such reorganization, reclassification, recapitalization, consolidation, merger, transfer, dissolution, liquidation or winding-up and a description in reasonable detail of the transaction. Such notice shall be mailed at least ten (10) Business Days prior to the date therein specified.

 

Section 11.                                    Lost, Mutilated or Missing Warrants. Upon receipt by the Company of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of any Warrant, and, in the case of loss, theft or destruction, upon receipt of indemnification satisfactory to the Company (in the case of an Initial Holder its unsecured, unbonded agreement of indemnity or affidavit of loss shall be sufficient) or, in the case of mutilation, upon surrender and cancellation of the mutilated Warrant, the Company shall execute and deliver a new Warrant of like tenor and representing the right to purchase the same aggregate number of Warrant Shares.

 

Section 12.                                    Waivers; Amendments. This Warrant may be modified or amended or the provisions hereof waived only with the written consent of the Company and the Warrant Holder. Any amendment or waiver effected in compliance with this Section shall be binding upon the Company and the Warrant Holder. The Company shall give prompt notice to the Warrant Holder of any amendment or waiver effected in compliance with this Section. No failure or delay of the Company or the Warrant

 

16

 

Holder in exercising any power or right hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of any such right or power, or any abandonment or discontinuance of steps to enforce such a right or power, preclude any other or further exercise thereon or the exercise of any other right or power. No notice or demand on the Company in any case shall entitle the Company to any other or future notice or demand in similar or other circumstances. The rights and remedies of the Company and the Warrant Holder hereunder are cumulative and not exclusive of any rights or remedies which it would otherwise have.

 

Section 13.                                    Miscellaneous.

 

(a)                                 Shareholder Rights. The Warrant shall not entitle any Warrant Holder, prior to the exercise of the Warrant, to any rights as a shareholder of the Company, except as set forth herein.

 

(b)                                 Expenses. The Company shall pay all reasonable expenses of the Warrant Holder, including reasonable fees and disbursements of counsel, in connection with the preparation of the Warrant, any waiver or consent hereunder or any amendment or modification hereof (regardless of whether the same becomes effective), or the enforcement of the provisions hereof; provided that the Company shall not be required to pay any expenses of the Warrant Holder arising solely in connection with a transfer of the Warrant.

 

(c)                                  Successors and Assigns. All the provisions of this Warrant by or for the benefit of the Company or the Warrant Holder shall bind and inure to the benefit of their respective successors and assigns.

 

(d)                                 Severability. In case any one or more of the provisions contained in this Warrant shall be invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions contained herein shall not in any way be affected or impaired thereby. The parties shall endeavor in good faith negotiations to replace the invalid, illegal or unenforceable provisions with valid provisions the economic effect of which comes as close as possible to that of the invalid, illegal or unenforceable provisions.

 

(e)                                  Notices. Any notice or other communication hereunder shall be in writing and shall be sufficient if sent by first-class mail or courier, postage prepaid, and addressed as follows: (a) if to the Company, addressed to the Company at its address for notices as set forth below its signature hereon or any other address as the Company may hereafter notify to the Warrant Holder and(b) if to the Warrant Holder, addressed to such address as the Warrant Holder may hereafter from time to time notify to the Company for the purposes of notice hereunder.

 

(f)                                   Equitable Remedies. Without limiting the rights of the Company and the Warrant Holder to pursue all other legal and equitable rights available to such party for the other parties’ failure to perform its obligations hereunder, the Company and the Warrant Holder each hereto acknowledge and agree that the remedy at law for any failure to perform any obligations hereunder would be inadequate and that each shall be entitled to specific performance, injunctive relief or other equitable remedies in the event of any such failure.

 

(g)                                  Continued Effect. Rights and benefits conferred on the holders of Warrant Shares pursuant to the provisions hereof (including Section 6) shall continue to inure to the benefit of, and shall be enforceable by, such holders, notwithstanding the surrender of the Warrant to, and its cancellation by, the Company upon the full or partial exercise or repurchase hereof.

 

(h)                                 Confidentiality. The Warrant Holder agrees to keep confidential any proprietary information relating to the Company delivered by the Company hereunder; provided that nothing herein

 

17

 

shall prevent the Warrant Holder from disclosing such information: (i) to any holder of Warrants or Warrant Shares, (ii) to any Affiliate of any holder of Warrants or Warrant Shares or any actual or potential transferee of the rights or obligations hereunder that agrees to be bound by this Section 13(h), (iii) upon order, subpoena, or other process of any court or administrative agency or otherwise required by law, (iv) upon the request or demand of any regulatory agency or authority having jurisdiction over such party, (v) which has been publicly disclosed, (vi) which has been obtained from any Person that is not a party hereto or an affiliate of any such party, (vii) in connection with the exercise of any remedy, or the resolution of any dispute hereunder (viii) to the legal counsel or certified public accountants for any holder of Warrants or Warrant Shares, or (ix) as otherwise expressly contemplated by this Warrant.

 

(i)                                     Governing Law. THIS WARRANT SHALL BE CONSTRUED AND ENFORCED IN ACCORDANCE WITH THE INTERNAL LAWS OF THE STATE OF NEW YORK, EXCEPT AS OTHERWISE REQUIRED BY MANDATORY PROVISIONS OF LAW.

 

(j)                                    Section Headings. The section headings used herein are for convenience of reference only and shall not be construed in any way to affect the interpretation of any provisions of the Warrant.

 

18

 

IN WITNESS WHEREOF, the Company has caused this Warrant to be duly executed by its authorized signatory as of the day and year first above written.

 

	
 
    	
SteadyMed Ltd., an   Israeli incorporated company
    
	
 
    	
 
    
	
 
    	
By
    	
 
    
	
 
    	
Name:
    
	
 
    	
Title:
    
	
 
    	
 
    
	
 
    	
Address for Notices:
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
Telephone:
    
	
 
    	
Facsimile:
    

 

19

 

Exhibit A to Warrant

 

Form of Notice of Exercise

 

,20  

 

To: [                        ]

 

Reference is made to the Warrant dated           . Terms defined therein are used herein as therein defined.

 

The undersigned, pursuant to the provisions set forth in the Warrant, hereby irrevocably elects and agrees to purchase         Shares, and makes payment herewith in full therefor at the Exercise Price of $                in the following form:                                                            .

 

[If the number of Shares as to which the Warrant is being exercised is less than all of the Shares purchasable thereunder, the undersigned hereby requests that a new Warrant representing the remaining balance of the Shares be registered in the name of               , whose address is:                                .]

 

The undersigned hereby represents that it is exercising the Warrant for its own account or the account of an Affiliate for investment purposes and not with the view to any sale or distribution and that the Warrant Holder will not offer, sell or otherwise dispose of the Warrant or any underlying Warrant Shares in violation of applicable securities laws.

 

	
 
    	
[NAME OF WARRANT HOLDER]
    
	
 
    	
 
    	
 
    
	
 
    	
By
    	
 
    
	
 
    	
Name:
    	
 
    
	
 
    	
Title:
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
[ADDRESS OF WARRANT   HOLDER]
    

 

 

Exhibit B to Warrant

 

Form of Warrant Assignment

 

Reference is made to the Warrant dated             , issued by [                       ]. Terms defined therein are used herein as therein defined.

 

FOR VALUE RECEIVED                      (the “Assignor”) hereby sells, assigns and transfers all of the rights of the Assignor as set forth in such Warrant, with respect to the number of Warrant Shares covered thereby as set forth below, to the Assignee(s) as set forth below:

 

Number of Warrant Shares

 

	
Name(s) of Assignee(s)
    	
 
    	
Address(es)
    	
 
    	
Number of Warrant 
   Shares
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    

 

All notices to be given by the Company to the Assignor as the Warrant Holder shall be sent to the Assignee(s) at the above listed address(es), and, if the number of Shares being hereby assigned is less than all of the Shares covered by the Warrant held by the Assignor, then also to the Assignor.

 

In accordance with Section 7 of the Warrant, the Assignor requests that the Company execute and deliver a new Warrant or Warrants in the name or names of the assignee or assignees, as is appropriate, or, if the number of Shares being hereby assigned is less than all of the Shares covered by the Warrant held by the Assignor, new Warrants in the name or names of the assignee or the assignees, as is appropriate, and in the name of the Assignor.

 

The undersigned represents that the Assignee has represented to the Assignor that the Assignee is acquiring the Warrant for its own account or the account of an Affiliate for investment purposes and not with the view to any sale or distribution, and that the Assignee will not offer, sell or otherwise dispose of the Warrant or the Warrant Shares except under circumstances as will not result in a violation of applicable securities laws.

 

Dated:                  , 20  

 

	
 
    	
[NAME OF ASSIGNOR]
    
	
 
    	
 
    	
 
    
	
 
    	
By
    	
 
    
	
 
    	
Name:
    	
 
    
	
 
    	
Title:
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
[ADDRESS OF ASSIGNOR]
    

 

 

APPENDIX A

 

Black Scholes Option Pricing formula to be used when calculating the value of each new warrant to purchase one share in the Acquirer shall be:

 

 

CAcq = value of each warrant to purchase one share in the Acquirer

 

SAcq = price of Acquirer’s stock as determined by reference to the average of the closing prices on the securities exchange or Nasdaq Global Market over the 20-day period ending three trading days prior to the closing of the Corporate Reorganization described in Section 5(d) if the Acquirer’s stock is then traded on such exchange or system, or the average of the closing bid or sale prices (whichever is applicable) in the over-the-counter market over the 20-day period ending three trading days prior to the closing of the Corporate Reorganization if the Acquirer’s stock is then actively traded in the over-the-counter market, or the then most recently completed financing if the Acquirer’s stock is not then traded on a securities exchange or system or in the over-the-counter market.

 

TAcq = expiration date of new warrants to purchase shares in the Acquirer = TCorp

 

tAcq = date of issue of new warrants to purchase shares in the Acquirer

 

TAcq-tAcq = time until warrant expiration, expressed in years

 

σ = volatility = annualized standard deviation of daily log-returns (using a 262-day annualization factor) of the Acquirer’s stock price on the securities exchange or Nasdaq Global Market over a 20-day trading period, determined by the Warrant Holders, that is within the 100-day trading period ending on the trading day immediately after the public announcement of the Corporate Reorganization described in Section 5(d) if the Acquirer’s stock is then traded on such exchange or system, or the annualized standard deviation of daily-log returns (using a 262-day annualization factor) of the closing bid or sale prices (whichever is applicable) in the over-the-counter market over a 20-day trading period, determined by the Warrant Holder, that is within the 100-day trading period ending on the trading day immediately after the public announcement of the Corporate Reorganization if the Acquirer’s stock is then actively traded in the over-the-counter market, or 0.9525 (or 95.25%) if the Acquirer’s stock is not then traded on a securities exchange or system or in the over-the-counter market.

 

N = cumulative normal distribution function

 

 

ln = natural logarithm

 

λ = dividend rate of the Acquirer for the most recent 12-month period at the time of closing of the Corporate Reorganization.

 

KAcq = strike price of new warrants to purchase shares in the Acquirer = KCorp * (SAcq / SCorp)

 

r = annual yield, as reported by Bloomberg at time tAcq, of the United States Treasury security measuring the nearest time TAcq

 

d2 = d1- σ√(TAcq-tAcq)

 

 

Appendix B

 

Black Scholes Option Pricing formula to be used when calculating the value of each Warrant to purchase one share in the Company shall be:

 

 

CCorp = value of each Warrant to purchase one share in the Company

 

SCorp = price of Company stock as determined by reference to the average of the closing prices on the securities exchange or Nasdaq Global Market over the 20-day period ending three trading days prior to the closing of the Corporate Reorganization described in Section 5(d) if the Company’s stock is then traded on such exchange or system, or the average of the closing bid or sale prices (whichever is applicable) in the over-the-counter market over the 20-day period ending three trading days prior to the closing of the Corporate Reorganization if the Company’s stock is then actively traded in the over-the-counter market, or the then most recently completed financing if the Company’s stock is not then traded on a securities exchange or system or in the over-the-counter market.

 

TCorp = expiration date of Warrants to purchase shares in the Company

 

tCorp = date of public announcement of transaction

 

TCorp-tCorp = time until Warrant expiration, expressed in years

 

σ = volatility = the annualized standard deviation of daily log-returns (using a 262-day annualization factor) of the Company’s stock price on the securities exchange or Nasdaq Global Market over a 20-day trading period, determined by the Warrant Holders, that is within the 100-day trading period ending on the trading day immediately after the public announcement of the Corporate Reorganization described in Section 5(d) if the Company’s stock is then traded on such exchange or system, or the annualized standard deviation of daily-log returns (using a 262-day annualization factor) of the closing bid or sale prices (whichever is applicable) in the over-the-counter market over a 20-day trading period, determined by the Warrant Holder, that is within the 100-day trading period ending on the trading day immediately after the public announcement of the Corporate Reorganization if the Company’s stock is then actively traded in the over-the-counter market, or 0.9525 (or 95.25%) if the Company’s stock is not then traded on a securities exchange or system or in the over-the-counter market.

 

N = cumulative normal distribution function

 

 

ln = natural logarithm

 

λ = dividend rate of the Company for the most recent 12-month period at the time of closing of the Corporate Reorganization.

 

KCorp = strike price of warrant

 

r = annual yield, as reported by Bloomberg at time tCorp, of the United States Treasury security measuring the nearest time TCorp

 

d2 = d1- σ√(TCorp-tCorp)

 

 

SCHEDULE 1

 

Fourth Amended Investor Rights Agreement, dated February 24, 2014, by and among SteadyMed Ltd. and certain of its shareholders

 

29

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00260-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00260-of-00352.parquet"}]]